Northwestern University Feinberg School of Medicine
Skip to main content

Search Trials

For best results, use specific search terms. For example, instead of "brain tumor," try "glioblastoma." You can also contact the Clinical Trials Office at 312-695-1102 for assistance.

Trials
NU 1365-001: A Humanitarian Device Exemption Use Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma
Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells may be…
Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells may be effective treatment for liver cancer that cannot be removed by surgery. 

This phase II trial is studying how well radiolabeled glass beads work in treating patients with liver cancer that cannot be removed by surgery.

You may be eligible for this research study if you have unresectable cancer primarily in the liver (with the liver being the only site of disease or the dominant site of disease).
Salem, RiadSalem, Riad
  • Map it 201 E. Huron St.
    Chicago, IL
NCT00530010 STU00011036
More Info

For more information on this study please contact us:

Study Coordinator 1 312 695 1102
Copy
A Humanitarian Device Exemption Compassionate Use Protocol of TheraSphere for Treatment of Unresectable Metastatic Cancer to the Liver
RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass b…
RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells may be effective treatment for liver cancer that cannot be removed by surgery. PURPOSE: This phase II trial is studying how well radiolabeled glass beads work in treating patients with metastatic liver cancer that cannot be removed by surgery.
Salem, RiadSalem, Riad
NCT00532740 STU00011037
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Copy
NU 09B2: Case Control Study of Biomarkers of Breast Cancer Risk in Benign Biopsy Samples

This study is being conducted to better understand the causes of breast cancer. Currently, our ability to determine if a particular woman is at higher than average risk for breast cancer is only a little bette…

This study is being conducted to better understand the causes of breast cancer. Currently, our ability to determine if a particular woman is at higher than average risk for breast cancer is only a little better than flipping a coin. However, there is good reason to believe that we can obtain much more information by focusing directly on breast cells and looking at the biochemical changes that predate cancer. We expect that breast cells present in breast biopsy samples will be a practical place to look for such changes, and that this will help us to predict which women will get breast cancer. In the future, we could then focus on high risk women to offer them methods of breast cancer prevention and also to target them for early diagnosis. It may also mean that we could spare women who are at low risk for breast cancer from treatment that may have side effects, and from unnecessary testing or surgery. The breast tissue changes we will look for may involve alterations in genes or in proteins. If we find changes in genes in the breast, these may be harmless variations (like genes that explain eye color or height), or they may be harmful, possibly promoting the development of cancer. To tell whether the changes were acquired only in the breast, later in life, or whether you were born with them, we will need to compare the breast genes with your bloodline genes. We can do this by collecting a sample of saliva.

You may be eligible for this research study if you have had breast surgery in the past for either a benign breast problem or breast cancer. 

Khan, Seema Ahsan AhsanKhan, Seema Ahsan Ahsan
  • Map it 201 E. Huron St.
    Chicago, IL
STU00013577
More Info

For more information on this study please contact us:

Study Coordinator 1 312 695 1102
Copy
NU 09Z3: Evaluation of immune cell responses in blood of patients with colon, rectal, and pancreas cancer – A pilot study

This study is being done because it is not well understood how the immune system controls tumor growth. You will be asked to provide blood samples for this research study.

This study is being done because it is not well understood how the immune system controls tumor growth. You will be asked to provide blood samples for this research study.

You may be eligible for this research study if you have cancer of the colon, rectum or pancreasand are planning to undergo treatment or you are a healthy volunteer who has agreed to donate asmall amount of blood. 
Mulcahy, Mary FrancesMulcahy, Mary Frances
  • Map it 201 E. Huron St.
    Chicago, IL
STU00015014
More Info

For more information on this study please contact us:

Study Coordinator 1 312 695 1102
Copy
NU 00X3: Pathology Core Facility

The main purpose of this project is to collect samples for research. The samples will be stored at the Pathology Core Facility (PCF) of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University Medical School (NUMS). PCF serves as the centralized r…

The main purpose of this project is to collect samples for research. The samples will be stored at the Pathology Core Facility (PCF) of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University Medical School (NUMS). PCF serves as the centralized resource that addresses the sample collection needs for the research community. The samples collected can be used by researchers at Northwestern University and third party commercial and non-profit institutions who have approval from their Institutional Review Board (a committee which is responsible for the ethical oversight of the study) for their projects. 

You will be asked to donate a sample of blood. In addition, any extra tissue or fluid from what has been collected from you for your routine care will be used. Examples of samples include but are not limited to tissue, blood, urine, and bone marrow. 

Wei, Jian-JunWei, Jian-Jun
  • Map it 201 E. Huron St.
    Chicago, IL
STU00020989
More Info

For more information on this study please contact us:

Study Coordinator 1 312 695 1102
Copy
RTOG 0724 - A Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterecotmy
RATIONALE: Drugs used in chemotherapy, such as cisplatin, pacli…
RATIONALE: Drugs used in chemotherapy, such as cisplatin, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether chemotherapy and radiation therapy are more effective when given with or without additional chemotherapy in treating cervical cancer. PURPOSE: This randomized phase III trial is studying chemotherapy and pelvic radiation therapy to see how well they work when given with or without additional chemotherapy in treating patients with high-risk early-stage cervical cancer after radical hysterectomy.
Some of the eligibility criteria include:

- Participants must be 18 years old or older.
- Participants must have undergone radical hysterectomy prior to entering the study.
- Participants cannot be allergic to carboplatin, paclitaxel and/ or cisplatin.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Donnelly, EricDonnelly, Eric
  • Map it 201 E. Huron St.
    Chicago, IL
NCT00980954 STU00021457
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
NCI 01X1: Breast Cancer Program: Tissue and Specimen Collection Facility

The purpose of this research study is to help advance the scientific understanding of breast cancer. A portion of breast or skin tissue and a sample of blood, along with clinical information, will be collected and stored in a…

The purpose of this research study is to help advance the scientific understanding of breast cancer. A portion of breast or skin tissue and a sample of blood, along with clinical information, will be collected and stored in a database for research purposes only. 

Only tissue or fluid in excess of that required for clinical diagnosis and/or staging will be collected. Specific clinical data will include: treatment for cancer (surgical procedures, chemo or hormone therapy, radiation), cancer outcome (recurrence, metastases, death due to disease, and death without disease, alive, alive with disease). 

You may be eligible for this research study if you are a woman with breast cancer undergoing biopsy or surgical procedures for the diagnosis, treatment, or prevention of your cancer. 
Wei, Jian-JunWei, Jian-Jun
  • Map it 201 E. Huron St.
    Chicago, IL
STU00023488
More Info

For more information on this study please contact us:

Study Coordinator 1 312 695 1102
Copy
Peripheral Neuropathy Research Registry (PNRR)
National Peripheral Neuropathy Research Registry, a collection of different types of information, such as patient medical, family, and social histories and blood samples. The information is carefully maintained so that it can be studied repeatedly in t…
National Peripheral Neuropathy Research Registry, a collection of different types of information, such as patient medical, family, and social histories and blood samples. The information is carefully maintained so that it can be studied repeatedly in the future. The registry aims to help researchers’ access large amounts of information about people with PN. By using this registry, researchers will facilitate both basic and clinical research studies that will bring improved understandings of the etiology (origination) and pathogenesis (development) of PN. They will specifically ask why some patients with peripheral neuropathy develop neuropathic pain and others do not, and what the characteristics of patients with painful peripheral neuropathy are in terms of their symptoms, examination findings, and blood tests. Ultimately this research may result in improved diagnosis, more effective treatments, and possibly prevention.
Inclusion criteria: 1. Diabetic Peripheral Neuropathy 2. Chemo-therapy Induced Peripheral Neuropathy 3. HIV-induced Peripheral Neuropathy 4. Idiopathic Peripheral Neuropathy; Exclusion criteria: Any other type of Peripheral Neuropathy
Ajroud-Driss, SendaAjroud-Driss, Senda
  • Map it 675 N. St. Clair St. Suite 20-100
    Chicago, IL
STU00048864
More Info

For more information on this study please contact us:

Joslin, Benjamin 312 503 7504
Copy
NU 11B04: Breast Tissue Biomarkers of ER- Specific Cancer Risk that Are Valid Across Menstrual and Menopausal Status

The purpose of this study is to discover predictors of future cancer in the healthy tissue of the opposite breast as compared to tissue from women with no breast disease. 

<…

The purpose of this study is to discover predictors of future cancer in the healthy tissue of the opposite breast as compared to tissue from women with no breast disease. 

If you participate in this study and are having a preventive mastectomy, no extra tissue will be removed for this study. If you are not having a preventive mastectomy, we will perform a needle biopsy of your other breast for research purposes. If you do not have breast cancer, we will use a portion of the healthy tissue removed during your reduction or augmentation surgery for research.

You may be eligible for this research study if you fit into one of the following categories:

1. You have been diagnosed with breast cancer and you and your doctor have decided that you will benefit from a preventive mastectomy of your other (non-cancerous) breast, OR

2. You have been diagnosed with breast cancer on one side and will soon be having surgical or medical treatment for that cancer, OR

3. You have no evidence of breast disease and are scheduled to undergo either a breast reduction or breast augmentation surgery.

Khan, Seema Ahsan AhsanKhan, Seema Ahsan Ahsan
  • Map it 201 E. Huron St.
    Chicago, IL
STU00051134
More Info

For more information on this study please contact us:

Study Coordinator 1 312 695 1102
Copy
A Randomized Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in Cancer Patients with Depression and Anxiety
The primary goals of this study are to determine if rTMS is safe and tolerable in depressed cancer patients and to determine how well …
The primary goals of this study are to determine if rTMS is safe and tolerable in depressed cancer patients and to determine how well these two methods of rTMS work in treating cancer-related depression. You are being asked to take part in this study because you are a cancer patient in remission who is depressed currently. In the future, we hope to be able to use rTMS on depressed cancer patients who are actively receiving cancer treatment. However, since this is a preliminary study, we will only include patients in remission. Finally, anxiety often accompanies depression. So, we are also interested in understanding your current level of anxiety and how rTMS affects any anxiety that you might have. Your participation in this study will last for approximately seven weeks and will involve 31 visits.
Dokucu, Mehmet EDokucu, Mehmet E
NCT01701284 STU00063218
More Info

For more information on this study please contact us:

Fairchild, Melody Dawn 312 503 7071
Copy
The Genetics of Prostate Cancer in Active Surveillance
Our study uses saliva samples to detect whether or not active surveillance is the best option for the subject, based on their their genetic makeup and susceptibility to aggressive prostate cancer.
1. Patients diagnosed with prostate cancer
2. Patients with Gleason ≤ 3+3 prostate cancer
3. Patients with fewer than 3 cores involved with cancer. If a patient has 3 or more cores involved with cancer but still meets all pathologic criteria and after discussing risks and benefits does not want definitive treatment, he may still be eligible for active surveillance.
4. Patients with no more than 50% of any 1 core involved with prostate cancer. If a patient has more than 50% of any 1 core involved with prostate cancer but still meets all pathologic criteria and after discussing risks and benefits does not want definitive treatment, he may still be eligible for active surveillance.
5. Patients age > 18. Patients are typically offered AS if they are ≥ 60 years of age. However, if a man meets pathologic criteria and is < 60, he can be entered in AS if, after discussing risks and benefits, does not want definitive treatment.
6. Most patients will have PSA value ≤ 10 ng/ml. However, since PSA is prostate specific and not prostate cancer specific, many patients with elevated PSA levels > 10 ng/ml will not have prostate cancer, and PSA is elevated due to conditions such as BPH or inflammation. If a patient has a PSA value > 10 ng/ml, but still meets all pathologic criteria, he may still be eligible for active surveillance
Kundu, Shilajit DKundu, Shilajit D
  • Map it 201 E. Huron St.
    Chicago, IL
STU00059221
More Info

For more information on this study please contact us:

Khawaja, Faizan 312 694 2417
Copy
Hippocampal Predictors of Cognitive Impairment (HippoPCI) in Breast Cancer Patients
The purpose of this study is to improve our understanding of differences in size, shape and activity of a variety of brain areas that can occur in women with breast cancer undergoing adjuvant chemotherapy or hormonal …
The purpose of this study is to improve our understanding of differences in size, shape and activity of a variety of brain areas that can occur in women with breast cancer undergoing adjuvant chemotherapy or hormonal therapy, and how these brain areas are related to the development of mild cognitive impairment as the results of these treatments. This study involves obtaining pictures of the brain’s size, shape and activity using a Magnetic Resonance Imaging (MRI) device, a machine that uses a powerful magnet to obtain this information without using any radiation. This procedure has been used safely with humans in many different studies. Your part in this study will last for 1 to 2 years.
Female breast cancer patients between 40-70 years old
Wang, LeiWang, Lei
  • Map it 680 N. Lake Shore Dr.
    Chicago, IL
NCT01949376 STU00069634
More Info

For more information on this study please contact us:

Fairchild, Melody Dawn +1 312 503 7071
Copy
NU 12G11: The Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This phase II trial studies how well tivozanib works in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer. Tiv…
This phase II trial studies how well tivozanib works in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer. Tivozanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Matei, DanielaMatei, Daniela
  • Map it 201 E. Huron St.
    Chicago, IL
NCT01853644 STU00073756
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
SWOG 1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer, e3 Breast Cancer Study- evaluating everolimus with endocrine therapy.

This randomized phase III trial studies how well giving hormone therapy together with or without everolimus work in treating patients with breast cancer.

The purpose of this study is to see whether treatment with everolimus plus hormone treatment after chemotherapy will increase the time without your cancer returning. The current standard treatment after chemotherapy is hormone treatment alone. Everolimus is a drug currently approved for the treatment of patients with advanced or metastatic (cancer that has spread to other parts of the body) kidney or breast cancer. It is considered investigational for non-metastatic breast cancer patients. Investigational or experimental means that the study drug is currently being tested in breast cancer patients and is not approved for sale in the United States by the Food and Drug Administration (FDA). In this study you will get hormone treatment with either everolimus or with placebo (a pill with no medication). The combination of hormone-treatment and everolimus is experimental in patients with breast cancer.

You may be eligible for this research study if you are a woman/man with hormone responsive breast cancer that has already been removed by surgery and you have completed any required chemotherapy or radiation.

Flaum, LisaFlaum, Lisa
  • Map it 201 E. Huron St.
    Chicago, IL
NCT01674140 STU00082264
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whether comprehensive radiation therapy is more effective than standard radiation therapy in treating patients with breast cancer
Donnelly, EricDonnelly, Eric
  • Map it 201 E. Huron St.
    Chicago, IL
NCT01872975 STU00083782
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
NU 13S02: Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
The purpose of this study is to see whether a drug called regorafenib might be effective in treating angiosarcoma. This study is fo…
The purpose of this study is to see whether a drug called regorafenib might be effective in treating angiosarcoma. This study is for patients who have angiosarcoma that has gotten worse after they received chemotherapy. Regorafenib is a type of drug called a kinase inhibitor. Regorafenib interferes with how some kinase proteins work. Some of these kinases in cancer cells might normally help the cancer cells grow or form new blood vessels that could feed a growing tumor. By blocking these proteins, regorafenib may help stop the growth of certain cancers.
Agulnik, MarkAgulnik, Mark
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02048722 STU00087654
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
Epigenetic Markers of Bladder Cancer Progression
The purpose of this study is to better understand the expression of certain genes and genetic changes that occur in bladder tumors.
Male or female patients aged 40-89 identified to have a bladder lesion or mass concerning for urothelial carcinoma based on cystoscopy or imaging who are scheduled to undergo transurethral resection of bladder tumor (TURBT).
Meeks, Joshua JMeeks, Joshua J
STU00088853
More Info

For more information on this study please contact us:

Meeks, Joshua J 312 695 8146
Copy
A 36 month multi-center, open label, randomized, comparator study to evaluate the efficacy and safety of everolimus immunosuppression treatment in liver transplantation for hepatocellular carcinoma exceeding Milan criteria.
This study is a prospective Phase IV study to determine if the …
This study is a prospective Phase IV study to determine if the use of Everolimus results in lower liver tumor recurrence and improved patient and graft survival after liver transplant for hepatocellular carcinoma (HCC). The immunosuppressive comparators will be Everolimus and Tacrolimus therapy compared to Tacrolimus and Mycophenolic acid/Mycophenolate Mofetil. Primary outcomes data is disease free survival (the time from randomization to HCC recurrence or death). Secondary outcomes are rate of recurrence of Hepatitis C, problems related to wound healing, hernia repair within the first 12 months, hepatic arterial thrombosis, renal function, acute cellular rejection, post-transplant diabetes, hypertension, and hyperlipidemia.
Kulik, Laura MKulik, Laura M
NCT02081755 STU00083409
More Info

For more information on this study please contact us:

Bezler, Laura 312 694 0260
Copy
B-WELL-Mom (Breathe-Wellbeing, Environment, Lifestyle, and Lung Function)
This NIH funded research study is to better understand how the lungs function during pregnancy and how the immune system responds to pregnancy. This study will help us to better understand why some women with asthma experience…
This NIH funded research study is to better understand how the lungs function during pregnancy and how the immune system responds to pregnancy. This study will help us to better understand why some women with asthma experience worsening of their symptoms while others improve. Because pregnancy affects lung function and immune response of all women, we are looking for both women with and without asthma to participate. The study consists of 4 clinic visits (1st, 2nd, and 3rd trimesters of pregnancy and 4 months postpartum), and an at-home diary.
-Pregnant women at least 18 years old.
-Less than 15 weeks pregnant with a single baby.
-Women with and without asthma are eligible to participate. -No diagnosis of Multiple Sclerosis, Lupus, Rheumatoid Arthritis, HIV, or Mixed Connective Tissue Disease.
Grobman, William AGrobman, William A
STU00093038
More Info

For more information on this study please contact us:

Wolfe, Kaitlin A 312 503 3248
Copy
DRUG ATI001-102: A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Subjects with Recurrent or Progressive Glioblastoma or Grade III Malignant Glioma
This research study involves two investigational drugs…
This research study involves two investigational drugs, veledimex, an activator ligand (INXN-1001) in combination with an Adenovirus Vector Engineered to Express hIL-12 (INXN-2001). IL-12 is a protein that may improve the body's natural response to disease by enhancing the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor. The main purpose of this study is to evaluate the safety and tolerability of a single tumor injection of INXN-2001 given in combination with oral veledimex.
Inclusion Criteria: 1. Male or female subjects ≥ 18 and ≤ 75 years of age. 2. Histologically confirmed supratentorial glioblastoma or other WHO grade III or IV malignant glioma from archival tissue. 3. Evidence of tumor recurrence/progression by MRI (RANO criteria) post standard initial therapy. 4. Previous standard of care anti-tumor treatment including surgery and/or biopsy and chemoradiation. 5. Able to undergo standard MRI scans with contrast agent. 6. Karnofsky Performance Status ≥ 70. 7. Adequate bone marrow reserves and liver and kidney function. 8.Male and female subjects must agree to use a highly reliable method of birth control. Exclusion Criteria: 1. Radiotherapy within 4 weeks or less prior to starting first veledimex dose. 2. Subjects with clinically significant increased intracranial pressure or uncontrolled seizures. 3. Known immunosuppressive disease, autoimmune conditions, and /or chronic viral infections. 4. Use of systemic antibacterials, antifungals or antivirals for the treatment of acute clinically significant infection. 5. Use of enzyme-inducing anti-epileptic drugs (EIAED) within 7 days prior to the first dose of study drug. 6. Other concurrent clinically active malignant disease requiring treatment. 7. Nursing or pregnant females. 8. Prior exposure to veledimex. 9. Presence of any contra-indication for a neurosurgical procedure.
Lesniak, MaciejLesniak, Maciej
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02026271 STU00094296
More Info

For more information on this study please contact us:

Amidei, Christina 312 695 9124
Copy
ECOG 1910: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults.
Purpose This study in being done to determine what affects (good and bad) the therapy blinatumomab has on acute lymphoblastic leukemia (ALL). Overview …
Purpose This study in being done to determine what affects (good and bad) the therapy blinatumomab has on acute lymphoblastic leukemia (ALL). Overview This study is for patients who have recently been diagnosed with a subtype of ALL that is known as BCR-ABL negative B-lineage ALL. Blinatumomab is a new antibody therapy that binds to B cells and recruits T cells to attack leukemia B cells. Patients will be randomized to receive chemotherapy what has traditionally been used to treat this sub-type of ALL alone or chemotherapy with blinatumomab . Studies are being done in ALL and other blood cancers with blinotumomab Blinatumomab has been effective in residual or relapsed B-cell ALL at destroying these specific cells. But it has not yet been proven helpful in combination with chemotherapy in newly diagnosed ALL. Description of Treatment There are several steps of treatment in this study. They are called induction, intensification, consolidation, and maintenance. In these study steps participants will be getting standard chemotherapy treatments that may or may not be combined with a new cancer drug called blinatumomab. Blinatumomab is a drug that is given as a continues infusion. The treatment schedule should be discussed with the study doctor.
Some of the eligibility criteria include:

- Participants in this study must have B lineage ALL that is Philadelphia chromosome and BCR/ABL negative. Please discuss this requirement with the study doctor.
- Participants must be 35-70 years old.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Dinner, ShiraDinner, Shira
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02003222 STU00093458
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
NU 14H04: Phase II Study of Romidepsin plus Lenalidomide for Patients with Previously Untreated PTCL
The purpose of this study is to evaluate how safe and effective the combination of the study drugs romidepsin and lenalidomide is for treating patients with peripheral t-cell lymp…
The purpose of this study is to evaluate how safe and effective the combination of the study drugs romidepsin and lenalidomide is for treating patients with peripheral t-cell lymphoma (PTCL) who have not been previously treated for this cancer. Currently, there is no standard treatment for patients with PTCL; the most common treatment used is a combination of drugs called CHOP, but this can be a difficult treatment to tolerate because of side effects, and is not particularly effective for most patients with PTCL. Romidepsin (Istodax®) is a type of drug called an HDAC inhibitor. It interacts with DNA (genetic material in cells) in ways that can stop tumors from growing. It is given as an infusion through the veins. Lenalidomide (Revlimid®) is a type of drug known as an immunomodulatory drug, or IMID for short. This drug affects how tumor cells grow and survive, including affecting blood vessel growth in tumors. It is given as an oral tablet (by mouth).
Some of the eligibility criteria include:

- Participants must have PTCL.
- Participants may not have had prior systemic treatment for their PTCL. Treatment with corticosteroids is allowed. Please discuss all treatments with the study doctor.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Pro, BarbaraPro, Barbara
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02232516 STU00097620
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
Development of a Kidney Cancer Patient Outcomes Database
Purpose This study is evaluating an on-line registry for kidney cancer patients called ‰ÛÏMyQOL,‰Û which stands for My Quality of Life. Overview A registry is a repository (database) of information about a group of people who …
Purpose This study is evaluating an on-line registry for kidney cancer patients called ‰ÛÏMyQOL,‰Û which stands for My Quality of Life. Overview A registry is a repository (database) of information about a group of people who share a common characteristic - in this case, kidney cancer. MYQOL registry participants enter information about their disease, treatment, symptoms, health status, and quality of life into an on-line, password-protected database on a regularly scheduled basis. Participants can use the registry to track many of their symptoms and their health status over time and to compare themselves (anonymously) with other groups of people (for example, how their level of fatigue compares with the average level of fatigue reported by other participants in the registry). Participants can also choose to share relevant information about themselves (from the registry) with their health care provider(s), by printing copies of their completed forms. Registry participants will be offered opportunities to join in other research studies when available. Description of Treatment Participants in this study will be asked to do the following for a 1-year trial period: 1) enroll in the on-line registry; 2) complete questionnaires about their health and treatment every 3 months ; and 3) be willing to have MYQOL researchers contact them confidentially about participating in other research studies. This does not mean that participants are obligated to participate in future research studies; only that they agree to be contacted.
Some of the eligibility criteria include:

- Participants must have a kidney cancer diagnosis.
- Participants must be 18 or older.
- Participants must be able to read English well enough to complete questionnaires.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Cella, DavidCella, David
  • Map it 201 E. Huron St.
    Chicago, IL
STU00070200
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
Behavioral activation and varenicline for smoking cessation in depressed smokers
The goal of this study is to develop a new combined treatment to help individuals with clinical depression to quit smoking. Participants will receive one of four treatments: 1) Standard behavior therapy + placebo; 2) Beh…
The goal of this study is to develop a new combined treatment to help individuals with clinical depression to quit smoking. Participants will receive one of four treatments: 1) Standard behavior therapy + placebo; 2) Behavioral activation for smoking cessation + placebo; 3) Standard behavior therapy + varenicline (Chantix); or 4) Behavioral activation for smoking cessation + varenicline (Chantix).
1. Adult (18 years of age or older) daily cigarette smokers (1+ cigarettes per day)
2. Lifetime history of clinical depression (Major Depressive Disorder)
Hitsman, Brian LHitsman, Brian L
NCT02378714 STU00100303
More Info

For more information on this study please contact us:

Reyes, Celine 1 877 236 7487
Copy
A prospective, randomized, blinded, placebo-controlled, phase IIb trial of an autologous tumor lysate (TL) + yeast cell wall particles (YCWP) + dendritic cells (DC) vaccine vs unloaded YCWP + DC in stage III and stage IV (resected) melanoma to prevent recurrence
The majority of melanoma…
The majority of melanoma vaccines tested to date have been antigen-specific vaccines targeting melanoma-specific or associated antigens and utilizing a variety of delivery systems and immune-adjuvants. As opposed to testing an "off the shelf" vaccine that might be able to treat a subset of patients, our approach has been personalized to the patient and applicable to all patients. Our vaccine approach consists of harnessing the most potent antigen presenting cell in the body - the dendritic cell (DC) - together with the full repertoire of tumor antigens from an individual's cancer. We have conducted phase I and II studies using an autologous DC-tumor cell fusion technique that has now been simplified into a DC-tumor cell lysate vaccine. The autologous tumor lysate (TL) is loaded into yeast cell wall particles (YCWP) that are naturally and efficiently taken up into the patient's DC. These autologous tumor lysate, particle-loaded, DC (TLPLDC) are injected intradermally (ID) monthly x 3 followed by boosters at 6, 12, and 18 months.
Chandra, SunandanaChandra, Sunandana
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02301611 STU00200122
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
NRG HN001: Randomized Phase II And Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
There are two study questions the investigators are asking in this randomized phase II/III trial b…
There are two study questions the investigators are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard concurrent chemotherapy and radiation therapy. When this standard treatment is completed, if there is no detectable EBV DNA in their plasma, then patients are randomized to either standard adjuvant cisplatin and fluorouracil chemotherapy or observation. If there is still detectable levels of plasma EBV DNA, patients will be randomized to standard cisplatin and flurouracil chemotherapy versus gemcitabine and paclitaxel. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, fluorouracil, gemcitabine hydrochloride, and paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cisplatin and fluorouracil is more effective than gemcitabine hydrochloride and paclitaxel after radiation therapy in treating patients with nasopharyngeal cancer.
Mittal, Bharat BMittal, Bharat B
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02135042 STU00200330
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
NU 14S03: A Phase II Study of Pazopanib with Oral Topotecan in Patients with Metastatic and Non-resectable Soft Tissue and Bone Sarcomas
The purpose of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control sarcomas. The…
The purpose of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control sarcomas. The safety of this drug combination will also be studied. Pazopanib hydrochloride and topotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Agulnik, MarkAgulnik, Mark
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02357810 STU00200112
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
Alliance A081105: Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Purpose The purpose of this study is to compare any good and bad effects patients may have when treated with the st…
Purpose The purpose of this study is to compare any good and bad effects patients may have when treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (an investigational drug). Overview This study is for patients with early stage non-small cell lung cancer that was surgically removed and may have been treated with chemotherapy and/or radiation. The tumor removed has a mutation of a gene called EGFR (Epidermal Growth Factor Receptor). Researchers are trying to find out if this mutation could help doctors make decisions about which type of treatment is best for people with this type of cancer. People not in a research study are usually not treated with anything after they finish their chemotherapy although some of them may receive radiation therapy. Description of Treatment This study has two study groups. Group 1 will get the study drug called erlotinib. The erlotinib will be taken once a day. Group 2 will get the placebo, which looks just like the erlotinib but does not have any active ingredients. The placebo will be taken once a day.
Some of the eligibility criteria include:

- Participants must have NSCLC.
- Participants must EGFR mutant and ALK rearrangement, which is detected by genetic testing performed through the study doctor's office.
- Participants must be 18 or older.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Mohindra, NishaMohindra, Nisha
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02193282 STU00200145
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
Ex vivo interactions between high-density-like nanoparticles and human blood
This research is significant because the high-density lipoprotein like nanoparticles (HDL-NPs) being investigated have been shown to have tremendous therapeutic properties when evaluated in in vitro and in vivo settings. Pr…
This research is significant because the high-density lipoprotein like nanoparticles (HDL-NPs) being investigated have been shown to have tremendous therapeutic properties when evaluated in in vitro and in vivo settings. Prior to initiating large-scale in vivo animal and human studies it is imperative that we obtain an in-depth knowledge of the interaction of the HDL-NPs with human blood cells using safe ex vivo experiments.
Healthy, non-pregnant adult (age >18-75 years) volunteers.
Thaxton, Colby SThaxton, Colby S
  • Map it 201 E. Huron St.
    Chicago, IL
STU00200368
More Info

For more information on this study please contact us:

Thaxton, Colby S 312 503 1826
Copy
A Phase 3 Multicenter, Randomized, Placebo-Controlled Study to Determine the Efficacy of Topical SGX301 and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma
To evaluate the safety and effectiveness of the topical ointment (cream), SGX301, in combination with light the…
To evaluate the safety and effectiveness of the topical ointment (cream), SGX301, in combination with light therapy in patients with cutaneous T-cell lymphoma.
Must be 18 years of age or older, with a clinical diagnosis of Cutaneous T- Cell Lymphoma, Myucosis Fungoides, Stage IA. Stage IB, or Stage IIA, and willing to refrain from sunbathing for duration of the study.
Guitart, JoanGuitart, Joan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT02448381 STU00200530
More Info

For more information on this study please contact us:

Jimenez, Javier 312 503 5903
Copy
NU 14H09: A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients with MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen
The purpose of this study is to evaluate the effects, good and bad of a new drug called ixazomib (also called MLN9708), when it…
The purpose of this study is to evaluate the effects, good and bad of a new drug called ixazomib (also called MLN9708), when it is given along with a common treatment combination, called Dose-Adjusted EPOCH-R (DA-EPOCH-R, for short). This is a type of study called a phase I/II trial. In the phase I part, the dose of the study drug (ixazomib) will be adjusted (either up or down) to find the maximum (highest) dose that does not cause excessive (too many) harmful side effects. In the phase II part, this dose of ixazomib will be given at the maximum safe dose found in phase I. In both phase I and II, DA-EPOCH-R will be adjusted between cycles depending on how blood cell levels are affected between cycles. Ixazomib is considered investigational because it is not approved by the U.S. Food and Drug Administration (FDA). DA-EPOCH-R is a combination chemotherapy treatment developed over the last 14-15 years, and each of the drugs in this regimen is FDA-approved and considered part of the standard of care.
Some of the eligibility criteria include:

- Participants must have diffuse large B-cell lymphoma (DLBCL) or other aggressive B-cell lymphoma that has an MYC-rearrangement. This is determined with special laboratory testing.
- Participants may not have had more than one prior cycle of chemoimmunotherapy for their lymphoma. All treatments should be discussed with the study doctor.
- Participants must be 18 or older.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Pro, BarbaraPro, Barbara
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02481310 STU00200596
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
A Prospective Study of Early Stage Breast Cancer Patients with Abnormal Myocardial Deformation treated with Anthracycline and/or Trastuzumab and Pertuzumab-based cancer therapy.
This study will help us to determine if prophylactic beta-blocker therapy, in patients with preclinical changes in LV funct…
This study will help us to determine if prophylactic beta-blocker therapy, in patients with preclinical changes in LV function, will prevent a worsening of strain, allowing patients to stay on their chemotherapy treatment.

Main Inclusion:

  • Patients > 18 years of age with HER2-overexpressing early stage breast cancer (Stages I – III)
  • Pathology report must include HER2 expression, estrogen and progesterone receptor status
  • Normal LV function (EF > 53%) on baseline echocardiogram
  • NYHA functional class I-II
  • Scheduled to receive treatment with anthracycline and/or trastuzumab and pertuzumab-based regimens

Main Exclusion:

  • Pre-existing cardiac disease (moderate-severe coronary artery disease, moderate-severe valvular heart disease, constrictive/restrictive cardiomyopathies)
  • Metastatic breast cancer
  • Prior use of BB/ACE therapy
  • 2nd and 3rd degree AV block, Sick Sinus Syndrome, severe bradycardia (<50 BPM), or severe hypotension (SBP < 85 mmHg)
  • Severe liver dysfunction or moderate-severe asthma
Akhter, NausheenAkhter, Nausheen
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02993198 STU00200675
More Info

For more information on this study please contact us:

Brady, Caitlin 312 926 5968
Copy
ECOG-ACRIN 1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Breast Cancer following Neoadjuvant Chemotherapy

The main purpose of this study is to compare getting more treatment with capecitabine (i.e. on…

The main purpose of this study is to compare getting more treatment with capecitabine (i.e. one of the usual approaches), to getting more treatment with a platinum-based chemotherapy (using the drug cisplatin or carboplatin), after surgery.

Platinum agents (cisplatin or carboplatin) are already FDA-approved to be used in patients with stage IV (i.e., metastatic) breast cancers, but are usually not used in patients with early forms of breast cancer. Getting a platinum-based chemotherapy after surgery could reduce the risk of cancer returning (metastatic recurrence) in the breast or at other distant organs, but it could also cause side effects. This study will allow the researchers to know whether this different approach is better, the same, or worse than using capecitabine chemotherapy. 

You may be eligible for this research study if you:

  • Have early stage breast cancer. 
  • Have a breast cancer that does not have the estrogen, progesterone or HER2 receptor, and is called triple-negative breast cancer.
  • Have completed all your chemotherapy prior to your surgery.
  • Had ≥ 1 cm worth of cancer in the breast at the time of your surgery.

Flaum, LisaFlaum, Lisa
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02445391 STU00201173
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
NU 15B01: A Single Arm Phase II Study Evaluating the Efficacy and Safety of Durvalumab (MEDI4736) in Combination with Tremelimumab in Patients with Metastatic HER2 Negative Breast Cancer: TNBC Expansion Cohort
The main purpose of this study is to determine the anti-tumor activity of MEDI4…
The main purpose of this study is to determine the anti-tumor activity of MEDI4736 in combination with tremelimumab in patients with metastatic HER2-negative breast cancer. Both MEDI4736 and tremelimumab are antibodies (proteins used by the immune system to fight infections and cancers). MEDI4736 attaches to a protein in tumors called PD-L1. It may prevent cancer growth by helping certain blood cells of the immune system get rid of the tumor. Tremelimumab stimulates (wakes up) the immune system to attack the tumor by inhibiting a protein molecule called CTLA-4 on immune cells. Combining the actions of these drugs may result in better treatment options for patients with breast cancer.
Cristofanilli, MassimoCristofanilli, Massimo
NCT02536794 STU00200984
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Copy
x(CIRB) NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
This randomized phase II/III trial studies how well standard of care therapy with stereotactic…
This randomized phase II/III trial studies how well standard of care therapy with stereotactic radiosurgery and/or surgery works and compares it to standard of care therapy alone in treating patients with breast cancer that has spread to one or two locations in the body (limited metastatic) that are previously untreated. Standard of care therapy comprising chemotherapy, hormonal therapy, biological therapy, and others may help stop the spread of tumor cells. Radiation therapy and/or surgery is usually only given with standard of care therapy to relieve pain; however, in patients with limited metastatic breast cancer, stereotactic radiosurgery, also known as stereotactic body radiation therapy, may be able to send x-rays directly to the tumor and cause less damage to normal tissue and surgery may be able to effectively remove the metastatic tumor cells. It is not yet known whether standard of care therapy is more effective with stereotactic radiosurgery and/or surgery in treating limited metastatic breast cancer.
Strauss, Jonathan BStrauss, Jonathan B
NCT02364557 STU00201769
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Copy
SMART Weight Loss Management
SMART is a 12-month weight loss research study taking place in the Department of Preventive Medicine at Northwestern University. SMART includes a 3-month weight loss program at no cost. The purpose of this research is to determine the best initial strategy for weight loss…
SMART is a 12-month weight loss research study taking place in the Department of Preventive Medicine at Northwestern University. SMART includes a 3-month weight loss program at no cost. The purpose of this research is to determine the best initial strategy for weight loss and best follow-up approach for those who need more support from a weight loss program
You are between the ages of 18 - 60 years old.
You will live in the Chicagoland area for the next 12 months.
You are NOT currently pregnant, trying to become pregnant, or breastfeeding.
You do NOT have an unstable medical condition.
You own an Android or iPhone smartphone.
You are willing to track your lifestyle behaviors using a smartphone for 3 months.
Spring, BonnieSpring, Bonnie
  • Map it 680 N. Lake Shore Drive Suite 1410
    Chicago, IL
NCT02997943 STU00202075
More Info

For more information on this study please contact us:

Scanlan, Laura 312 503 1395
Copy
Sense2Stop: Mobile Sensor Data to Knowledge
Sense2Stop is a 15-day smokingcessation research study that involves answering surveys on a study-providedsmartphone, smoking cessation counseling, 3 in-person lab sessions, andwearable sensors to detect smoking, eating, and stress. The aim of this res…
Sense2Stop is a 15-day smokingcessation research study that involves answering surveys on a study-providedsmartphone, smoking cessation counseling, 3 in-person lab sessions, andwearable sensors to detect smoking, eating, and stress. The aim of this research is to build systems that can recognize when peopleare stressed and then provide them with relaxation prompts in the moment toreduce their likelihood of being stressed, smoking, or overeating in the nearfuture. Using these systems should help smokers be more effective in theirattempts to quit by reducing their tendency to lapse when they are stressed orexperiencing other negative moods or behaviors.
-Age: 18 to 65 years old ; Smokes 1+ cigarettes/day for past year. ; Willing to try to quit smoking for at least 48 hours during a 15-day quit trial. ; Will not use non-cigarette tobacco products or nicotine replacement
therapy during the study period ; Not taking or intending to take pharmacological smoking cessation aids
(e.g., nicotine replacement, bupropion, venlafaxene) during the study
period
Spring, BonnieSpring, Bonnie
  • Map it 680 N. Lake Shore Dr.
    Chicago, IL
NCT03184389 STU00201566
More Info

For more information on this study please contact us:

Daly, Elyse 312 503 1317
Copy
A large-scale multicenter phase II study evaluating the protective effect of a tissue selective estrogen complex (TSEC) in women with newly diagnosed ductal carcinoma in situ.
The main purpose of this study is to determine if taking the study drug, conjugated estrogens/bazedoxife…
The main purpose of this study is to determine if taking the study drug, conjugated estrogens/bazedoxifene (Duavee®) causes any changes in the proliferation markers within the breast tissue of the study subjects. The study drug is approved by the US Food and Drug Administration in healthy postmenopausal women to treat certain symptoms of menopause such as hot flashes. Since it is not approved in women with DCIS, its use in this study is experimental. This study will also look at whether taking the study drug causes any significant or undesirable side effects in women with DCIS. The researchers hope that this study will help them determine if taking the study drug is safe in women taking DCIS and if it can possibly reduce the risk of developing breast cancer in women with DCIS.
Some of the eligibility criteria include:

- Participants must be postmenopausal women with newly diagnosed DCIS scheduled to undergo surgical therapy.
- Patients must be able to swallow the oral medication.
- Patients must be able to understand and the willing to sign a written informed consent document and comply to all procedures.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Kulkarni, SwatiKulkarni, Swati
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02694809 STU00202100
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
The Role of Hormone Receptors in Breast Cancer Development in BRCA1/2 Mutation Carriers

The purpose of this research study is to determine how the hormones estrogen, progesterone, and cortisone may work through their receptor proteins to help breast cancers to develop in women with BRCA1 and BRCA2…

The purpose of this research study is to determine how the hormones estrogen, progesterone, and cortisone may work through their receptor proteins to help breast cancers to develop in women with BRCA1 and BRCA2 mutations. At the moment, the only proven way to prevent breast cancer for women with BRCA mutations is bilateral mastectomy (removal of both breasts). In this study, we will test the effects of selective hormone receptor modulators on breast cells derived from BRCA1 and BRCA2 mutation carriers. If this works in the way we think it will, we may then be able to develop new ways of preventing cancers in BRCA mutation carriers.

Participation will consist of a one-time questionnaire, blood draw, and tissue collection at the time of your scheduled surgery.

You may be eligible for this research study if you fit into one of the following categories: 

1) you have been diagnosed with breast cancer and you and your doctor have decided that you will benefit from a preventive mastectomy of your other (non-cancerous) breast, or 

2) you are a BRCA1 or BRCA2 mutation carrier with no evidence of breast cancer and are scheduled to undergo a preventive mastectomy of both breasts, or 

3) you have no evidence of breast disease and are scheduled to undergo breast reduction surgery.

Khan, Seema Ahsan AhsanKhan, Seema Ahsan Ahsan
  • Map it 201 E. Huron St.
    Chicago, IL
STU00202331
More Info

For more information on this study please contact us:

Study Coordinator 1 312 695 1102
Copy
NU 15B08: A Phase II Single Arm Study of Palbociclib in Patients with Metastatic HER2-positive Breast Cancer with Brain Metastasis
Purpose The purpose of this study is to evaluate if the study drug palbociclib has anti-tumor activity against the breast cancer that has spread to the brain. And to d…
Purpose The purpose of this study is to evaluate if the study drug palbociclib has anti-tumor activity against the breast cancer that has spread to the brain. And to determine the overall radiographic response rate in the CNS. Overview Palbociclib is an anti-cancer medication that has been shown to stop cancer cells from growing. It has been approved in hormone positive breast cancer, along with other hormone therapies and has been found to be effective. The preclinical studies suggest that the drug may also have activity in other types of breast cancer, such as triple negative and HER2 positive breast cancer. The study drug palbociclib is a small molecule and can penetrate the meninges. The purpose of this study is to see if the study drug is effective in patients with brain metastasis, who have triple negative and HER2-positive breast cancer. Description of Treatment All study participants will get the study drug in the form of a pill that will be taken once a day for 21 days followed by a 7 day break. These 28 days is considered as one cycle. The participants with HER2-positive breast cancer may also receive trastuzumab (standard of care) concurrently.
Some of the eligibility criteria include:

- Participants who have been diagnosed with triple negative or HER2-positive metastatic breast cancer.
- Participants must have been treated previously with more than two lines of chemotherapy for metastatic disease.
- Participants must be 18 or older.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Cristofanilli, MassimoCristofanilli, Massimo
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02774681 STU00202582
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
Culturally Adapted Cognitive Behavioral Stress and Self-Management (C-CBSM) Intervention for Prostate Cancer
Este estudio está diseñado para ayudar a los hombres a mejorar la calidad de vida y reducir los síntomas del cáncer de próstata. El estudio imparte habilidades de manejo de estrés y prom…
Este estudio está diseñado para ayudar a los hombres a mejorar la calidad de vida y reducir los síntomas del cáncer de próstata. El estudio imparte habilidades de manejo de estrés y promueve la salud. Este programa de salud e intervención para hombres diagnosticados con cáncer de próstata, ofrece información sobre cómo reducir el estrés y aprender a relajarse. Este estudio dentro Northwestern University está financiado por el Instituto Nacional del Cáncer. El objetivo del estudio es examinar cómo los programas de salud pueden mejorar la calidad de vida de los hombres tratados por cáncer de próstata.
(a) ≥ 18 years of age;
(b) Hispanic/Latino self-identification;
(c) Spanish speakers (including bilinguals who express interest in a Spanish-based psychosocial intervention); (d) Willingness to be randomized and followed for approximately 12 months.
(d) Primary diagnosis of localized Prostate Cancer (T1-T3, N0, M0);
(e) Surgical or radiation treatment (e.g., external beam, brachytherapy, proton) within the past 48 months prior to participating in the study
Miller, GregMiller, Greg
  • Map it 633 N. St. Clair St.
    Chicago , IL
NCT03344757 STU00203197
More Info

For more information on this study please contact us:

Pizarro, Edgar 312 503 3949
Copy
NU 16I01: Phase I/Ib study of nivolumab in combination with Therasphere (yttrium-90) in patients with advanced hepatocellular carcinoma.
Purpose The purpose of this study is to identify maximum tolerated dose (MTD), that is, the highest dose of the study drug nivolumab that does not cause unaccept…
Purpose The purpose of this study is to identify maximum tolerated dose (MTD), that is, the highest dose of the study drug nivolumab that does not cause unacceptable side effects, for combination treatment of nivolumab and Y-90. Also, to evaluate the efficacy (the effect of drug on your tumor) and the tolerability (the effect of the drug on your body) of nivolumab, when given with standard of care Y-90 (Therasphere). Overview Nivolumab is currently FDA approved for other cancers, but has not yet been investigated in advanced or refractory hepatocellular carcinoma. Nivolumab is an antibody (a human protein that sticks to a part of the tumor and/or immune cells) designed to allow the body‰Ûªs immune system to work against tumor cells. Y-90 is currently FDA approved for the treatment of hepatocellular carcinomas, but has not yet been investigated in combination with nivolumab for this disease. This is a phase I study of 2 drugs used in combination: nivolumab and Y-90. We think the combination of these drugs may be more effective against your cancer. Description of Treatment All study participants will get the same study intervention. All study participants will get the study drug Nivolumab. You will receive induction treatment with Y-90, and then approximately four weeks after, you will receive Nivolumab once every 2 weeks (given through the vein over 30 minutes). After you finish your treatment with nivolumab, the study team will continue to watch you for side effects for up to 30 days from your last treatment. If you discontinue from the study for any reason, the study team will continue to check how you are doing every 2 weeks for up to 24 weeks from the start of your treatment.
Some of the eligibility criteria include:

- Patients must have a diagnosis of hepatocellular carcinoma.
- Patients must have advanced disease that is not amenable to transplant or resection.
- Patients may be treatment naÌøve or have received any number of prior therapies

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Kalyan, AparnaKalyan, Aparna
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02837029 STU00203003
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
A Phase 2, single arm, multi-center, open label trial Combining Optune with concurrent Bevacizumab in the setting of Recurrent or Progressive Meningioma
Purpose The purpose of this research study is to determine the effects (good and bad) bevacizumab (the study drug) combined with Optune (the stud…
Purpose The purpose of this research study is to determine the effects (good and bad) bevacizumab (the study drug) combined with Optune (the study device) tumor treatment field therapy has on meningiomas. Overview Bevacizumab (the study drug) is considered investigational because the US Food and Drug Administration (FDA) has not approved its use for the treatment of meningiomas. The study drug is a medication that blocks the growth of new blood vessels. In order for tumors to grow they need to have a blood supply. Tumor cells have been shown to produce substances that stimulate the abnormal growth of new blood vessels that allow the tumor to grow. It is thought that the study drug may interfere with the growth of new blood vessels and therefore might stop tumor growth, and possibly shrink the tumor by keeping it from receiving nutrients and oxygen supplied by the blood vessels. Optune (the study device) is also considered investigational because the US Food and Drug Administration (FDA) has not approved its use for the treatment of meningiomas. The study device, Optune is a device that the patient will wear and use for at least 18 hours of each day. It delivers alternating electrical current to the patient‰Ûªs brain tumor and by doing so interrupts a process called mitosis. Mitosis needs to occur in order for cell division to occur and allows tumors to grow. By slowing this process, we hypothesize that meningioma growth may also be slowed. Description of Treatment Tumor treatment field therapy with Optune will be initiated at the same time as bevacizumab, with both treatments to start within a one-week period of each other. Bevacizumab will be given at current standard central nervous system (CNS) dosing of 10mg/kg q2 weeks in an outpatient setting. After 4 cycles (1 cycle=28days) of therapy (Cycle 5 day 1) patients may choose to switch to bevacizumab at a dose of 15 mg/kg q3 weeks. For patients who chose to make this switch, they have to do it on Day1 of a new cycle. Tumor treatment fields with Optune will be delivered for at least 18 hours a day at a frequency of 200 KHz and intensity of 1-3V/cm. Treatment will be continued until disease progression or up to 1 year.
"Some of the eligibility criteria include:

- Patients must be age = 18 years. Both males and females and patients from all

ethnic backgrounds are eligible.
- Patients must have a histologic diagnosis of meningioma, WHO grade 2 or 3 (atypical or anaplastic).
- All patients must have developed recurrent disease/progression after receiving all standard treatments.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial."
Kumthekar, PriyaKumthekar, Priya
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02847559 STU00203030
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
A Double Blind, Randomized, Vehicle Controlled, Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients with the Mycosis Fungoides (MF) or Sézary Syndrome (SS) Forms of Cutaneous T-Cell Lymphoma (CTCL)
The main goal of …
The main goal of this study is to test the efficacy and safety of topical Naloxone for itching in patients with MF.
21 years of age or older with a diagnosis of mycosis fungoides (MF) with itching present on a daily basis for more than one month and willing to fill out a diary for 7 days to provide severity of itch before enrollment.
Guitart, JoanGuitart, Joan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT02811783 STU00203078
More Info

For more information on this study please contact us:

Jimenez, Javier 312 503 5903
Copy
DRUG AG-221-AML-005: A phase 1B/2 open-label, randomized study of 2 combinations of isocitrate dehydrogenase (IDH) mutant targeted therapies plus azacitidine: oral AG-120 plus subcutaneous azacitidine and oral AG-221 plus SC azacitidine in subjects with newly diagnosed acute myeloid leukemia harboring an IDH1 or an IDH2 mutation, respectively, who are not candidates to receive intensive induction chemotherapy

The purpose of this study, which involves research, is to determine a safe and tolerable dose of the investigational combination of AG-120 plus azacitidine or AG-221 plus azacitidine (Phase 1b) as well as the effectiveness of AG-221 plus azacitidine in treating this disease, when compared to azacitidine alone (Phase 2). AG-120 is not currently approved for the treatment of any type of AML and its use in this study is investigational. Recently AG-221, also known as

enasidenib (IDHIFA®), was approved in the United States (US) for the treatment of adult patients with relapsed or refractory AML with an Isocitrate dehydragenase 2 (IDH2) mutation as detected by an FDA-approved test. The use of enasidenib in this study is investigational. Enasidenib is not currently approved in other countries for the treatment of any type of AML. Azacitidine (Vidaza®) is approved in Canada for the treatment of AML for patients with 20 - 30% bone marrow blast and multi lineage dysplasia, according to WHO classification, who are not candidates to receive hematopoietic stem cell transplantation.

- Adults at least 18 years of age

- Newly diagnosed, primary (i.e., de novo) or secondary (Progression of MDS or myeloproliferative neoplasms [MPN], or therapy-related) AML according to WHO classification with at least 20% leukemic blasts in the bone marrow

- Have an IDH1 or IDH2 gene mutation

- Not candidates to receive intensive IC.

Frankfurt, OlgaFrankfurt, Olga
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02677922 STU00203231
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
The purpose of this study is to find if adding the study drug, nivolumab (also known as OPDIVO®), will limit lung cancer…
The purpose of this study is to find if adding the study drug, nivolumab (also known as OPDIVO®), will limit lung cancer from growing back in patients with early stage non-small cell lung cancer. Nivolumab is a drug that may turn on the body's immune system to attack any cancer cells that may remain after surgery. The addition of nivolumab may help prevent your cancer from returning, but it could also cause side effects. This research study will allow researchers to find out whether this different treatment is better, the same, or worse than the usual treatment for lung cancer. The study drug, nivolumab, is already FDA-approved for use in non-small cell lung cancer that has previously been treated with chemotherapy. The use of nivolumab in this study is investigational (not approved by the FDA) in this type of cancer. 
You may be eligible if you have non-small cell lung cancer, which has been removed by a surgeon. 
Mohindra, NishaMohindra, Nisha
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02595944 STU00203600
More Info

For more information on this study please contact us:

Study Coordinator 1 312 695 1102
Copy
NUDB 16Z01: The OncoSET Program Database and Biobank - Combining Clinical Outcomes with Next Generation Sequencing and other Advanced Molecular Testing for Genetic Aberrations in Patients with Advanced Solid Malignancies

The purpose of the study is to gather information about your cancer and the t…

The purpose of the study is to gather information about your cancer and the treatment you receive as a part of your routine clinical care. In this study, we are developing a research registry, which is a bank of information about many patients.

We are interested in learning about the relationship between your cancer and the different types of tests available to identify the best treatment option for you. That is, we are interested in the tests that identify possible ‘mutations’ (e.g., changes) or ‘drivers’ within your tumor, what treatments you receive after getting these tests, and how your cancer responds to the treatments.

The tests known as next generation sequencing or “NGS” are usually done on your cancer tissue or blood samples as a part of your routine clinical care. Your doctor can use the information to identify the best treatment option for you after discussing it with other doctors. These routine tests will be performed whether you participate in this study or not, but we want to collect the information about this process for this study.

If you participate in this study, extra samples of your blood will be collected and stored, and your health information from your medical record and NGS lab results will be collected and stored.

You may be eligible for this research study if you have a diagnosis of cancer and are being treated at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Cristofanilli, MassimoCristofanilli, Massimo
  • Map it 201 E. Huron St.
    Chicago, IL
STU00203944
More Info

For more information on this study please contact us:

Study Coordinator 1 312 695 1102
Copy
OT-15-001: A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy
Purpose The purpose of this study i…
Purpose The purpose of this study is to measure how well and how safe eflornithine is in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has come back after radiation and chemotherapy. Overview Elfornithine is an experimental drug. An experimental drug means that the United States Food and Drug Administration (FDA) has not approved it for use. This drug will be used with another drug called Lomustine that is approved by the FDA in the United States for patients with anaplastic astrocytoma. Description of Treatment This study has two study groups. Patients will be randomly placed in one of the 2 groups.
Some of the eligibility criteria include:

- Participants must be 18 years of age or older.

- Patients must have surgical or biopsy proven diagnosis of WHO grade 3 Anaplastic Astrocytoma

Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Kumthekar, PriyaKumthekar, Priya
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02796261 STU00203957
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
NU 16U05: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects
Purpose The purpose of this research is to study two US FDA approved drugs alone or in combination with each other in p…
Purpose The purpose of this research is to study two US FDA approved drugs alone or in combination with each other in people who have metastatic castration-resistant prostate cancer and specific changes in their DNA, to see which one is best at keeping prostate cancer from growing. Metastatic castration-resistant prostate cancer means the cancer is spreading outside of the prostate and does not stop or go away with hormone therapy or surgery to reduce testosterone. One of the drugs, Olaparib, is not FDA approved for prostate cancer, which means it is experimental or investigational. Overview Once prostate cancer has progressed to metastatic castration-resistant prostate cancer, standard treatment focuses on extending life, delaying disease progression, and improving symptoms and quality of life. The purpose of this research is to study two US FDA approved drugs alone and in combination with each other in people who have metastatic castration-resistant prostate cancer and DNA repair defects. One of the drugs, Olaparib, is not FDA approved for prostate cancer. People who take part in this research study have been diagnosed with metastatic castration-resistant prostate cancer and either their body or the the cancer have a genetic defect (flaw) that causes problems with their body‰Ûªs ability to repair damage to their DNA. Description of Treatment Participants will be placed into one of four groups. The treatment that each group will receive is as follows. Group 1 will receive Abiraterone (1000 mg by mouth once per day) and prednisone (5 mg by mouth twice per day). Group 2 and 4 will receive Olaparib (300 mg by mouth twice per day). Group 3 will receive Olaparib (300 mg by mouth twice per day), Abiraterone (1000 mg by mouth once per day) and prednisone (5 mg by mouth twice per day). Treatment may continue until disease progression, severe or unacceptable side effects, or until the participant or study doctor think the treatment should stop.
Some of the eligibility criteria include:

- participants must have been diagnosed with prostate cancer that is metastatic (has spread outside of the prostate region) and castration-resistant (means the cancer is still growing even when testosterone levels are close to zero)
- participants must be males 18 years of age or above

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Hussain, MahaHussain, Maha
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03012321 STU00203960
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
NU 16C01: A Phase 0 first-in-human study using NU-0129: a spherical nucleic acid (SNA) gold nanoparticle targeting BCL2L12 in recurrent glioblastoma multiforme or gliosarcoma patients
Purpose The purpose of this research study is to evaluate the safety of NU-0129 SNA gold nanoparticle infusion in …
Purpose The purpose of this research study is to evaluate the safety of NU-0129 SNA gold nanoparticle infusion in patients with recurrent glioblastoma multiforme or gliosarcoma Overview This is a first-in-human trial to determine the safety of NU-0129. The study drug is composed of a small gold nanoparticle that has spherical nucleic acid attached to it. This small particle allows NU-0129 to cross the blood brain barrier (a filtering mechanism that carry blood to the brain). Once within the tumor, the nucleic acid component is able to target a gene called Bcl2L12 that is present in glioblastoma multiforme, and is associated with tumor growth. This gene prevents tumor cells from apoptosis, which is the process of programmed cell death, thus promoting tumor growth. Researchers think that targeting the Bcl2L12 gene with NU-0129 will help stop cancer cells from growing. Description of Treatment All study participants will receive the same study drug, NU-0129, given through vein one time over 20 minutes as an inpatient. Within two days of getting this drug, participants will have a tumor resection surgery, recommended by their doctor. The study team will continue to watch for any side effects for at least 4 weeks with clinic visits and lab tests done each week. The study team will also continue to check how the subjects are doing with a clinic visit at least every 3 months for up to 2 years or until their disease comes back.
Some of the eligibility criteria include:

- Patients should have a diagnosis of recurrent glioblastoma multiforme (GBM) or gliosarcoma (GS) after failing prior therapy.
- Eligible patients must be surgical candidates where surgery is felt to be an appropriate treatment option.
- Patients must be 18 or older.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Kumthekar, PriyaKumthekar, Priya
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03020017 STU00203790
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
NU 16H07: Phase II Trial of Pembrolizumab in Combination with ICE Salvage Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma
The purpose of this research study is to evaluate a new drug Pembrolizumab in combination with chemotherapy, for Relapsed/Refractory Hodgkin Lymphoma. The chemotherapy regim…
The purpose of this research study is to evaluate a new drug Pembrolizumab in combination with chemotherapy, for Relapsed/Refractory Hodgkin Lymphoma. The chemotherapy regimen is called “ICE” and includes three drugs: ifosfamide, carboplatin, and etoposide. Pembrolizumab is currently FDA approved for the treatment of melanoma, but has not yet been investigated in Relapsed/Refractory Hodgkin Lymphoma. The ‘ICE’ regimen of chemotherapy is currently FDA approved for the treatment of Relapsed/Refractory Hodgkin Lymphoma, but has not yet been investigated in combination with pembrolizumab for this disease. This is a phase II study of these drugs used in combination. For patients who have a relapse of their Hodgkin’s lymphoma, retreatment with chemotherapy followed by a stem cell transplant is recommended. We know that obtaining a complete remission (not able to detect any disease on scans) is very important prior to proceeding to the stem cell transplant. Patients with negative scans have a lower chance of the disease coming back and a higher chance of achieving a long-term cure. Research continues to find for the best regimen to obtain a complete remission in this setting.
Some of the eligibility criteria include:
• Patients must have a histologically confirmed diagnosis of classical Hodgkin lymphoma.
• Patients must have relapsed/refractory disease, with at least one line of prior chemotherapy, but not more than 2 prior lines of treatment, for Hodgkin lymphoma.
• Patients must be 18 or older.
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Winter, Jane NormaWinter, Jane Norma
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03077828 STU00203658
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
A Randomized Phase II Study of Topical Steroids as Preemptive Therapy for Epidermal Growth Factor Receptor Inhibitor-Induced Papulopustular Eruption
EGFR inhibitors are biologic agents used to treat certain cancers including non-small cell lung, colorectal, head and neck, and pancreatic carcinomas. T…
EGFR inhibitors are biologic agents used to treat certain cancers including non-small cell lung, colorectal, head and neck, and pancreatic carcinomas. These agents often have a side effect of an acne like rash that in some cases can be quite severe. This rash has been shown to be inflammatory in origin but is currently treated with antibiotics if it appears. The main goal of this study is to test if patients treated with steroid cream, (added) which is an anti-inflammatory medication, (added) before a rash develops have a less severe rash than patients who do not use a steroid cream before a rash develops.
Must be 18 years of age or older with a diagnosis of cancer and starting an (changed from 'and') EGFR inhibitor. During the study you must be willing to fill out a daily diary, use sunscreen and cream daily, and fill out 2 questionnaires and have photographs taken every 2 weeks for 4 visits.
Choi, JenniferChoi, Jennifer
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03115567 STU00203631
More Info

For more information on this study please contact us:

Kosche, Cory 312 503 5944
Copy
NU 16L04: Parallel proof of concept phase 2 study of nivolumab and metformin combination treatment in advanced non-small cell lung cancer with and without prior treatment with PD-1/PD-L1 inhibitors
The purpose of this study is to find the benefits of combining nivolumab with metformin in advanced non…
The purpose of this study is to find the benefits of combining nivolumab with metformin in advanced non-small cell lung cancer with and without prior treatment with immunotherapy. We will also be looking at the safety of the combination. Nivolumab is currently approved in certain cancers such as melanoma, lung cancer and kidney cancer. Metformin is approved by the US Food and Drug Administration (FDA) to treat diabetes. In this study, Metformin is being used to treat cancer. This use is not approved by the FDA; therefore, in this study, it is considered experimental. Experimental means the U.S. FDA has not approved the drug for use in your type of cancer. All study participants will get the same study intervention. All study participants will get the study drugs Nivolumab and Metformin.
You may be eligible for this research study if you have an advanced non-small cell lung cancer, and are age 18 or older. 
Chae, Young KwangChae, Young Kwang
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03048500 STU00204354
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
Phase II study of nivolumab and ipilimumab for treatment of advanced adenoid cystic carcinoma and non-adenoid cystic carcinoma
Purpose The purpose of this study is to look at the efficacy (the effect on the tumor) and the safety (the effect on the body) of the study drugs when given as a combinati…
Purpose The purpose of this study is to look at the efficacy (the effect on the tumor) and the safety (the effect on the body) of the study drugs when given as a combination in participants with this type of cancer. Another purpose of the study is to see which tumor markers (proteins in the blood that the body produces in response to the cancer) lead to better results in participants treated with the study drugs. Overview Nivolumab and ipilimumab are antibodies, which are human proteins that recognize and attach to a part of the tumor and/or body‰Ûªs immune cells. They work in slightly different ways to activate the immune system and help the body‰Ûªs immune system to work against tumor cells. The combination of these drugs is already approved by the FDA to treat advanced melanoma (a type of skin cancer). Nivolumab and ipilimumab are investigational because they are not approved by the FDA to be used for the type of cancer being studied. Description of Treatment All study participants will receive the same study drugs, nivolumab/ipilimumab combination, over periods called cycles (1 cycle = 12 weeks / 84 days). Nivolumab will be given through a vein over 30 minutes once every 2 weeks for the first 16 weeks. It will then be given over 60 minutes once every 4 weeks for as long as participants are benefitting. Ipilimumab will be given through a vein over 90 minutes every 6 weeks (twice each cycle). Participants will take part in the study as long as they are benefitting from the study drugs.
Some of the eligibility criteria include:

- Participants must be > 18 years old.
- Participants must have histologically or cytologically confirmed metastatic/recurrent adenoid cystic carcinoma (ACC) or non-adenoid cystic carcinomas (non-ACC) of major or minor salivary glands

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Matsangou, MariaMatsangou, Maria
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03146650 STU00204579
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
(xIRB) DRUG 2215-CL-0201: A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
Purpose The purpose of the study is to see if a medicine called ASP2215 given alone or in combination with azacitidine is both effective and safe as a treatment for AML patients with mutations in the FLT3 gene when compared to being treated with azacitidine alone. Overview ASP2215 is a drug that is designed to slow down the growth of leukemic cells by blocking FLT3 protein on those cells. ASP2215 is an experimental drug that is being studied to treat AML. It is being tested in clinical trials and has not been approved by U.S. Food and Drug Administration (FDA) and/or any other regulatory authorities for any indication. Description of Treatment Participants will be randomly (like flipping a coin) assigned to one of three treatment groups: * Group A: ASP2215 given alone; * Group AC: ASP2215 given in combination with azacitidine chemotherapy; * Group C: azacitidine chemotherapy given alone. During the treatment period, the study is divided into periods of time called cycles. Each cycle lasts 28 days. Participants will come into the clinic each cycle for visits to get more study drug and to evaluate AML and other related health assessments.
Some of the eligibility criteria include:

- Participant is at least 18 years old.
- Subject has a diagnosis of previously-untreated AML.
- Subject is positive for FLT3 mutation (ITD or TKD [D835/I836] mutation) in bone marrow or whole blood.

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Dinner, ShiraDinner, Shira
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02752035 STU00203834
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
The Molecular Markers of Bladder Cancer
Genetic research may discover genes, find out how genes function, or help researchers learn how to use what we know about genes to treat or prevent and treat disease. The purpose is to study whether the results of genetic testing can predict if bladder cancer i…
Genetic research may discover genes, find out how genes function, or help researchers learn how to use what we know about genes to treat or prevent and treat disease. The purpose is to study whether the results of genetic testing can predict if bladder cancer is going to recur, progress (get worse), or respond to chemotherapy.
Male or female patients ages 40-89 with high-grade T1 bladder cancer or patients with muscle invasive (>T2) bladder cancer undergoing neoadjuvant chemotherapy and radical cystectomy.
Meeks, Joshua JMeeks, Joshua J
STU00204352
More Info

For more information on this study please contact us:

312 695 8146
Copy
A PHASE I STUDY OF NEURAL STEM CELL BASED VIROTHERAPY IN COMBINATION WITH STANDARD RADIATION AND CHEMOTHERAPY FOR MALIGNANT GLIOMA
Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease in great need of novel therapeutic approaches. Bas…
Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease in great need of novel therapeutic approaches. Based on the encouraging results of our preclinical studies which demonstrate improved efficacy without added toxicity, the paradigm of delivering a novel oncolytic adenovirus via a neural stem cell line in combination with radiation and chemotherapy is well-suited for evaluation in newly diganosed malignant gliomas. The standard-of-care allows application of virotherapy as neoadjuvant therapy and assessment of the cooperative effects with radiation/chemotherapy without altering the standard treatment.
Inclusion Criteria:
•Patients must have presumed malignant glioma based on clinical and radiologic evaluation (pathologic confirmation of malignant glioma must be made at the time of stereotactic biopsy or resection prior to NSC-CRAd-S-pk7 injection; if this is not possible, the injection will not be performed and the subject will no longer be eligible for the study).
•Tumor must be accessible for injection and must not be located in the brainstem, or contained within the ventricular system.
•Planning to undergo standard radiation/chemotherapy
•18 years of age or older.
•Performance status must be KPS ≥ 70
•SGOT (AST) < 3x upper limit of normal
•Serum creatinine < 2mg/dl
•Platelets > 100,000/mm3 and WBC > 3000/mm3

Exclusion Criteria:
•Prior or ongoing liver disease including known cirrhosis, hepatitis B or C infection but not to exclude patients with a distant history of resolved hepatitis A infection.
•Immunosuppressive drugs (with exception of corticosteroid).
•Known HIV+ patients.
•Acute infections (viral, bacterial or fungal infections requiring therapy).
•Pregnant or breast-feeding patients.
•Evidence of metastatic disease or other malignancy (except squamous or basal cell skin cancers).
•Prior radiation therapy to the brain or prior treatment for brain tumor Other serious co-morbid illness or compromised organ function
Lesniak, MaciejLesniak, Maciej
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03072134 STU00203933
More Info

For more information on this study please contact us:

Amidei, Christina 312 695 9124
Copy
NCI 2015-06-04 Phase IIB trial of neoadjuvant oral tamoxifen versus transdermal 4-hydroxytamoxifen in women with DCIS of the breast
Phase IIB trial of neoadjuvant oral tamoxifen versus transdermal 4-hydroxytamoxifen in women with DCIS of the breast
Khan, Seema Ahsan AhsanKhan, Seema Ahsan Ahsan
  • Map it 250 E. Superior St.
    Chicago, IL
NCT02993159 STU00204804
More Info

For more information on this study please contact us:

Xu, Yanfei 1 312 472 0595
Copy
Melanoma and Skin Cancer Tissue Repository

The purpose of this study is to allow researchers studying and treating melanoma and other cancers to have access to tissue for research purposes only. Northwestern University may use your medical record information, as well as tumor, blood, saliva, urine…

The purpose of this study is to allow researchers studying and treating melanoma and other cancers to have access to tissue for research purposes only. Northwestern University may use your medical record information, as well as tumor, blood, saliva, urine, and fecal samples (collectively called “tissue”) for research studies to help us understand melanoma and other skin cancers. Biopsies and surgery of your cancer will not be a part of this study but will be performed as part of your standard care.

You may be eligible to take part in the research component of the Northwestern Melanoma and Skin Cancer Tissue Repository if you are either a new or returning patient and have a skin cancer or pre-cancer lesion. 

Sosman, JeffreySosman, Jeffrey
  • Map it 201 E. Huron St.
    Chicago, IL
STU00204151
More Info

For more information on this study please contact us:

Study Coordinator 1 312 695 1102
Copy
BTCRC GYN15-013: Phase II Study of Pembrolizumab in Combination with Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma
The purpose of this study is to test the good and bad effects of the study drug, pembrolizumab, in combination with routine care using paclitaxel and ca…
The purpose of this study is to test the good and bad effects of the study drug, pembrolizumab, in combination with routine care using paclitaxel and carboplatin chemotherapy.
Participants will be adults with cancer in the lining of the uterus (endometrium) that has spread to other parts of the body or has returned after initial treatment.
Matei, DanielaMatei, Daniela
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02549209 STU00204968
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
NCI 2015-06-03 Statin Therapy to Reduce Disease Progression from Liver Cirrhosis to Cancer
The purpose of this study is to compare the safety and effects of simvastatin in people with liver cirrhosis who are at an increased risk for liver cancer. In this study, you will get either simvastatin 40 mg d…
The purpose of this study is to compare the safety and effects of simvastatin in people with liver cirrhosis who are at an increased risk for liver cancer. In this study, you will get either simvastatin 40 mg daily or placebo daily, a pill that looks like simvastatin 40 mg but contains no medication. Simvastatin is approved by the U.S. Food and Drug Administration (FDA) to reduce the risk for heart attack, stroke, and chest pain in patients who have heart disease or risk factors for heart disease such as smoking, high blood pressure, low high-density lipoprotein (HDL), or family history of early heart disease. It is also approved to lower the risk for heart attack or stroke in patients with type 2 diabetes and risk factors such as diabetic eye or kidney problems, smoking, or high blood pressure. However, simvastatin is not approved by the FDA to decrease the risk of liver cancer. Simvastatin is considered “investigational” (a study drug) in this study. Studies show that simvastatin lowers the risk of heart disease not only by decreasing cholesterol, but also by decreasing inflammation. We believe that this anti-inflammatory effect of simvastatin may help patients with liver cirrhosis.
Confirmed diagnosis of liver cirrhosis assessed by the presence of clinical signs, symptoms, body imaging (ultrasound, computed tomography [CT], or magnetic resonance imaging [MRI]), or liver biopsy
Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)
Leukocytes >= 2,500/microliter
Absolute neutrophil count >= 1,500/microliter
Platelets >= 50,000/microliter
Hemoglobin >= 10 g/dL
Total bilirubin =< 3 x institutional upper limit of normal (ULN)
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 5 x institutional ULN
Creatinine =< 1.5 x institutional ULN
Women who are able to become pregnant must have a confirmed negative pregnancy test result prior to enrollment; women >= 50 years of age who have not had a menstrual period in the past year; and women who have had a hysterectomy, both ovaries removed, or a tubal ligation; will not be required to have a pregnancy test
Women who are able to become pregnant must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately
Ability to understand and the willingness to sign a written informed consent document and medical release
Willing and able to comply with trial protocol and follow-up
Have had an abdominal imaging test (CT, MRI, or ultrasound) within the past 7 months
Kulik, Laura MKulik, Laura M
  • Map it 675 N. St. Clair St.
    Chicago, IL
NCT02968810 STU00204992
More Info

For more information on this study please contact us:

Sipich, Kimberly A 312 694 1293
Copy
(xIRB NCI CIRB) SWOG 1609 DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
Purpose The purpose of this study is to test any good and bad effects of the combination of study drugs called ipilimumab and nivolumab in treating rare cancers and cancers of unknown primary origin. Overview…
Purpose The purpose of this study is to test any good and bad effects of the combination of study drugs called ipilimumab and nivolumab in treating rare cancers and cancers of unknown primary origin. Overview The combination treatment of ipilimumab and nivolumab could shrink a participant's cancer but it could also cause side effects. Researchers hope to learn if the study drugs will shrink the cancer by at least one-quarter compared to its present size. Both ipilimumab and nivolumab have already been FDA-approved to treat other cancers. However, ipilimumab and nivolumab are investigational and not FDA-approved for use in combination in treating rare cancers or cancers of unknown primary origin. Description of Treatment All study participants will get the same study drugs: ipilimumab and nivolumab. Participants will receive both study drugs through a vein on the first day of each cycle (or every 6 weeks), and they will receive nivolumab through a vein every 2 weeks. Participants will continue to receive study drugs until their disease gets worse or they experience bad side effects from the study drugs or their study doctor decides that they are not benefiting from the study drugs.
Some of the eligibility criteria include:

- Participants must be at least 18 years of age or older.

No other prior malignancy is allowed except for the following:

1. Adequately managed Stage I or II cancer from which the participant is currently in complete remission

2. Any other cancer from which the participant has been disease free for one year.

3. Adequately managed Stage I or II follicular thyroid or prostate cancer is also eligible, in which the participant is not required to be in complete remission

Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Chae, Young KwangChae, Young Kwang
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02834013 STU00205572
More Info

For more information on this study please contact us:

Study Coordinator 1 312 695 1102
Copy
NU JH17U01: Overcoming drug resistance in metastatic castration-resistant prostate cancer with novel combination of TGF-β receptor inhibitor LY2157299 and enzalutamide: a randomized multi-site phase II study
This research is being done to test the effectiveness (anti-tumor activity) and safety ofcom…
This research is being done to test the effectiveness (anti-tumor activity) and safety ofcombining enzalutamide with LY2157299 for the treatment of men with advanced castrateresistant prostate cancer. 
Morgans, AliciaMorgans, Alicia
NCT00000417 STU00205208
More Info

For more information on this study please contact us:

Study Coordinator 1-855-NU-STUDY
Copy
MY PATHWAY: AN OPEN-LABEL PHASE IIA STUDY EVALUATING TRASTUZUMAB/PERTUZUMAB, ERLOTINIB, VEMURAFENIB/COBIMETINIB, VISMODEGIB, ALECTINIB, AND ATEZOLIZUMAB IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH MUTATIONS OR GENE EXPRESSION ABNORMALITIES PREDICTIVE OF RESPONSE TO ONE OF THESE AGENTS
Trastuzumab…
Trastuzumab/Pertuzumab combination, Erlotinib, Vemurafenib/Cobimetinib combination, Vismodegib, Alectinib and Atezolizumab are agents that target specific proteins that cause or contribute to the growth and spread of cancers. These targeted therapy agents have been tested and approved by the US FDA to treat some types of cancer but not others. The purpose of this research study is to evaluate whether these targeted drugs is safe and effective for the treatment of other types of cancers. Many cancers contain molecular abnormalities that cause or contribute to their ability to grow and spread. These molecular and genetic changes can be detected in the laboratory tests. By blocking the effects of these abnormalities, the growth of cancer may be stopped or slowed down. Many new cancer drugs work in this way. Because they block the effects of specific molecular abnormalities within the cancer, they are known as “targeted” agents. Patients are now able to have molecular tests done on their tumor tissue (“molecular profiling”), in order to identify potential molecular abnormalities that may be treated with targeted drugs. Some of these targeted drugs have been approved by the US FDA to treat certain types of cancer but not others. The purpose of this study is to evaluate if these targeted drugs is safe and effective for the treatment of other types of cancers.
Some of the eligibility criteria include:1) Molecular testing results from a certified lab showing an abnormality that can be targeted with any of the above agents; 2) Able to understand the nature of this trial and provide written informed consent; 3) Participants must be 18 or older.
Villaflor, VictoriaVillaflor, Victoria
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02091141 STU00205235
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
DRUG CA209-816: Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
The main purpose of this study is to look at the safety, tolerability, and overall effectiveness (how well the …
The main purpose of this study is to look at the safety, tolerability, and overall effectiveness (how well the drug works) of nivolumab in combination with ipilimumab and nivolumab in combination with plantinum doublet chemotherapy in subjects with non-small cell lung cancer.
Mohindra, NishaMohindra, Nisha
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02998528 STU00205030
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
NU UW16B13: A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer
Certain types of breast cancer test positive for overexpression HER2 (a protein involved in normal cell growth) and some test negative. Some patients may …
Certain types of breast cancer test positive for overexpression HER2 (a protein involved in normal cell growth) and some test negative. Some patients may have HER2-negative breast cancer with mutations in HER2. Neratinib is an investigational drug - meaning that it has not been approved by the U.S. Food and Drug Administration [FDA] - shown to be effective for treating HER2-positive breast cancer in clinical trials. An additional routine treatment involves a drug called Fulvestrant, which blocks the effects of estrogen in breast tissue. In this study, the uses of neratinib alone or in combination with Fulvestrant, will be studied, to see how the cancer responds to these treatments in each population.
Diagnosis with metastatic breast cancer at the time of screening
Diagnosis of metastatic breast cancer that is HER2-negative, but found to have a mutation in HER2 at the time of enrollment
Age of at least 18 years
Completion of radiation therapy and be at least 1 week from the last administration before starting study treatment
Cristofanilli, MassimoCristofanilli, Massimo
  • Map it 201 E. Huron St.
    Chicago, IL
NCT01670877 STU00205349
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
BTCRC-GI15-015: A Phase II Study of FOLFOX combined with Nab-Paclitaxel (FOLFOX-A) in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma

This study is being done to find out if a drug called nab-paclitaxel plus a combination chemotherapy regimen…

This study is being done to find out if a drug called nab-paclitaxel plus a combination chemotherapy regimen called FOLFOX have any effect on stomach cancer or cancer where the esophagus and the stomach meet. The study drugs could shrink your cancer but it could also cause side effects.

Nab-paclitaxel is a new formulation of a chemotherapy called paclitaxel. Regular paclitaxel is made with stabilizers that cause allergic reactions in many patients. Nab-paclitaxel does not use these stabilizers which means more of the drug can be given with fewer allergic reactions. Nab-paclitaxel (Abraxane®) is approved by the U.S. Food and Drug Administration (FDA) to treat breast, lung, and pancreas cancers. 

FOLFOX stands for a combination of three drugs: oxaliplatin, leucovorin, and 5-fluorouracil. Oxaliplatin is a chemotherapy approved by the FDA to treat colon and rectal cancer. Leucovorin is not a chemotherapy. It is form of folic acid and it is given with 5-fluorouracil to help increase the anti-cancer effects of 5-fluorouracil. It is approved by the FDA to be given with fluorouracil in patients with advanced colorectal cancer. 5-fluorouracil is approved by the FDA to treat cancers of the breast, stomach, colon, rectum, and pancreas.

Combining nab-paclitaxel with FOLFOX should be considered investigational. Investigational means that the FDA has not approved this combination of drugs for stomach cancer or cancer where the esophagus and the stomach meet.

You may be eligible for this research study if you have stomach cancer or cancer where the esophagus and the stomach meet, if you have not had any previous chemotherapy treatment, and if your cancer cannot be cured by surgery.

Benson III, Al BBenson III, Al B
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03283761 STU00205558
More Info

For more information on this study please contact us:

Study Coordinator 1 312 695 1102
Copy
Clinical Database of Nephrectomy at Northwestern University
The goal of this study is to determine the current clinical outcomes of our nephrectomy patients at Northwestern (such as complications and survival). We hope to keep track of patients for the first 5-years following radical or partial nep…
The goal of this study is to determine the current clinical outcomes of our nephrectomy patients at Northwestern (such as complications and survival). We hope to keep track of patients for the first 5-years following radical or partial nephrectomy in order to better understand the long-term behavior of the disease.
Patients ages 18-89 with a diagnosis of kidney cancer.
Nadler, Robert BNadler, Robert B
STU00205973
More Info

For more information on this study please contact us:

312 695 6124
Copy
(xIRB NCI-CIRB) SWOG 1512: A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unsectable Desmoplastic Melanoma (DM)
The purpose of this study is to test any good and bad effects of the study drug MK-3475 (also called pembrolizumab). MK-3475 (pembr…
The purpose of this study is to test any good and bad effects of the study drug MK-3475 (also called pembrolizumab). MK-3475 (pembrolizumab) could shrink your cancer but it could also cause side effects. Researchers hope to learn if the study drug will cause the cancer to at least temporarily disappear in more than twenty percent of patients with melanoma that is not surgically removable. In patients with melanoma that is surgically removable, researchers also hope to learn if the study drug will cause the surgery to be more effective and avoid repeated surgery.
Chandra, SunandanaChandra, Sunandana
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02775851 STU00205551
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) OR Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1 Agent"
The purpose of this study is to compare any good and bad effects of using ipilimumab in combination with nivolumab to th…
The purpose of this study is to compare any good and bad effects of using ipilimumab in combination with nivolumab to the usual approach of using ipilimumab alone when treating melanoma that cannot be removed by surgery. The combination treatment of ipilimumab and nivolumab could stop a participant's melanoma from getting worse, but it could also cause side effects. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. Both ipilimumab and nivolumab have already been FDA-approved to treat other cancers. However, ipilimumab and nivolumab are investigational and not FDA-approved for use in combination in treating melanoma. This study has two treatment groups, Group 1 and Group 2. Participants in Group 1 will receive ipilimumab once every three weeks for up to four times. Participants in Group 2 will receive nivolumab and ipilimumab once every three weeks for up to four times.
Participants must be at least 18 years of age. Participants must have melanoma that cannot be removed by surgery. Participants have received an immunotherapy drug (a drug that helps the body’s immune system destroy cancer cells), and their cancer got worse while receiving that.
Sosman, JeffreySosman, Jeffrey
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03033576 STU00205856
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator’s Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma
This research study is investigating a drug (that is called IMCgp100) in patients with a…
This research study is investigating a drug (that is called IMCgp100) in patients with advanced uveal melanoma. Uveal melanoma is generally treated with either chemotherapy or drugs that work by activating the immune system, known as immunotherapies. In this research study, IMCgp100 will be compared to three representative standard treatments: dacarbazine (a chemotherapy drug), ipilimumab (an immunotherapy drug targeting a protein called CTLA-4), or pembrolizumab (an immunotherapy drug targeting a protein called PD-1). This research study is being done to assess the efficacy and safety of the IMCgp100 in patients with uveal melanoma in comparison to these standard treatments.
Chandra, SunandanaChandra, Sunandana
  • Map it 201 E. Huron St.
    Chicago, IL
NCT00000418 STU00205550
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma
This research study is a phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational treatment to learn whether the inter…
This research study is a phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational treatment to learn whether the intervention works in treating a specific disease. “Investigational” means that the intervention is being studied. The Food and Drug Administration (FDA) has approved Nivolumab as treatment for advanced renal cell carcinoma, however discontinuation of nivolumab and the combination with Ipilimumab are investigational. Nivolumab is an antibody (type of human protein) drug that may stimulate your body’s immune system to fight tumor cells. Ipilimumab is also an antibody that may stimulate your body’s immune system to fight tumor cells. Ipilimumab is FDA approved for the treatment of melanoma (skin cancer) and has been previously studied in renal cell cancer. Specifically, this study will look at the use of these treatments based on how your disease responds to the treatment. Both of these study drugs are given by IV (intravenous) through a vein. About 12 people are expected to participate in this research study here at Northwestern University out of 160 people in the entire study nationally.
Some of the eligibility criteria include:
• Participants must be 18 or older.
• Patient must have the ability to understand and sign an approved informed consent form (ICF).
• Patient must have a confirmed diagnosis of advanced Renal Cell Carcinoma (RCC).
Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.
Sosman, JeffreySosman, Jeffrey
  • Map it 201 East Huron Street Suite 12-160​
    Chicago, IL
NCT03117309 STU00205969
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
Clinical Database of Prostate Cancer at Northwestern University
The goal of this study is to create a database of prostate cancer patients at Northwestern Memorial Group to better understand, learn about, prevent, treat or cure prostate cancer.
Men ages 18-89 years daignosed with prostate cancer.
Schaeffer, EdwardSchaeffer, Edward
STU00206270
More Info

For more information on this study please contact us:

Khawaja, Faizan 312 694 2417
Copy
ALLIANCE A021501 PREOPERATIVE EXTENDED CHEMOTHERAPY VS. CHEMOTHERAPY PLUS HYPOFRACTIONATED RADIATION THERAPY FOR BORDERLINE RESECTABLE ADENOCARCINOMA OF THE HEAD OF THE PANCREAS
The purpose of this study is to compare any good and bad effects of using chemotherapy compared to chemotherapy and radiati…
The purpose of this study is to compare any good and bad effects of using chemotherapy compared to chemotherapy and radiation prior to surgery. This study will allow the researchers to know whether which approach is better, the same, or worse than the other.
You may be eligible for this study if you have pancreatic cancer that cannot be removed by surgery at this time.
Kalyan, AparnaKalyan, Aparna
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02839343 STU00205727
More Info

For more information on this study please contact us:

Study Coordinator 1 312 695 1102
Copy
NU 16B19: Automated system for creating custom three-dimensional radiofrequency ablation lesion geometries in post-lumpectomy margin ablation breast cancer treatment

When a lumpectomy or excisional biopsy is performed to remove cancer, the surgeon attempts to create a cancer-free zone or “margin…

When a lumpectomy or excisional biopsy is performed to remove cancer, the surgeon attempts to create a cancer-free zone or “margin” around the removed area. In order to create this margin or safety zone, heat can be used to kill pre-cancerous or cancerous cells in the zone around where the cancer once existed. This process is called “ablation”. We wish to test an ablation method that can be added to future breast cancer surgeries. To do this, we need donated breast tissue from people who have mastectomies performed.

The heat source being investigated in this study is radiofrequency ablation (RFA). In this study a new RFA device design will be tested. These devices have a spacing applicator to form fit to the tissue around a lumpectomy for optimal treatment. These devices are in the development phase and have not yet been approved by the Food and Drug Administration (FDA), however, because the procedure is done on tissue that has been removed from the body, there is not a physical risk from the use of the device. This study will allow us to analyze the effectiveness of the devices and improve their use and design before they are used to treat breast cancer patients who receive lumpectomy.

You may be eligible for this research study if you are scheduled to undergo a mastectomy on one or both of your breasts. 

Bethke, KevinBethke, Kevin
  • Map it 201 E. Huron St.
    Chicago, IL
STU00206005
More Info

For more information on this study please contact us:

Study Coordinator 1 312 695 1102
Copy
NU 17U19: Cognitive Effects of Androgen Receptor (AR) Directed Therapies for Advanced Prostate Cancer

This study will help researchers understand what men go through when being treated for their cancer. Specifically, the purpose of this study is to:

1. Assess the way men think during treatme…

This study will help researchers understand what men go through when being treated for their cancer. Specifically, the purpose of this study is to:

1. Assess the way men think during treatment for prostate cancer during specific treatments for prostate cancer.

2. Follow the thinking process during prostate cancer treatment over time.

3. Identify genetic variations that might make men more or less sensitive to thinking changes during treatment for prostate cancer. Genes are the instruction manual for your body. The genes you get from your parents decide what you look like and how your body behaves. They can also tell us a person’s risk for certain diseases and how they will respond to treatment. 

You may be eligible for this research study if you have prostate cancer and are interested in helping researchers understand what men go through when being treated for their cancer. 
Morgans, AliciaMorgans, Alicia
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03016741 STU00206082
More Info

For more information on this study please contact us:

Study Coordinator 1 312 695 1102
Copy
PET/MRI using [18F]-DCFPyL for the Staging of Newly Diagnosed Prostate Cancer
This research study involves the use of a scanner that is capable of taking PET and MR images at the same time. A PET scan is a test that uses radioactive glucose (sugar) and a computer to create images of how organs and ti…
This research study involves the use of a scanner that is capable of taking PET and MR images at the same time. A PET scan is a test that uses radioactive glucose (sugar) and a computer to create images of how organs and tissues in the body are functioning. Abnormal cells in the body use glucose at a different rate than normal cells and this allows the scanner to create a detailed picture of how your body is working. A MR scan uses strong magnets and computers to created detailed images of the soft tissue in your body. The purpose of this study is to gain understanding how PET-MR (positron emission tomography-magnetic resonance imaging) using the substance 18F-DCFPyL (PyL) may help in diagnosing prostate cancer and in determining the stage of prostate cancer before surgery.
Men with biopsy-proven prostate cancer and a diagnosis of high risk, very high risk or locally advanced prostate cancer per NCCN guidelines.
Schaeffer, EdwardSchaeffer, Edward
NCT03392181 STU00205957
More Info

For more information on this study please contact us:

Khawaja, Faizan 312 694 2417
Copy
Shared Decision Making in Advanced Prostate Cancer
This study will help researchers understand what men go through when makingdecisions for treating their cancer. Specifically, the purpose of the study is to: 

1. Assess the treatment decision making process of men with advanced prostate cancer…

This study will help researchers understand what men go through when makingdecisions for treating their cancer. Specifically, the purpose of the study is to: 

1. Assess the treatment decision making process of men with advanced prostate cancer. 

2. Determine whether the amount of patient participation in decisions affects patientoutcomes, such as quality of life and satisfaction with the decision. 

3. Help researchers learn how to make treatment decision-making easier and lessconfusing for men with prostate cancer.

You may be eligible for this research study if you have prostate cancer and are interested in helping researchers understand what men go through when making decisions for treating their cancer.

Morgans, AliciaMorgans, Alicia
  • Map it 201 E. Huron St.
    Chicago, IL
STU00206080
More Info

For more information on this study please contact us:

Study Coordinator 1 312 695 1102
Copy
A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs host disease after allogeneic stem cell transplantation (REACH 3)
The purpose of the study is to find out if the drug ruxolitinib is safe and prov…
The purpose of the study is to find out if the drug ruxolitinib is safe and provides better treatment in comparison with “Best Available Therapy” in people who have chronic (does not get better over time) Graft-versus-Host-Disease that does not get better with steroid medications
Currently on steroids for GVHD post Allogenic Stem Cell Transplant.
Choi, JenniferChoi, Jennifer
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03112603 STU00206339
More Info

For more information on this study please contact us:

O'Hara, Lyndsey 312 503 5944
Copy
AN OPEN-LABEL, PHASE 2 STUDY OF NERATINIB IN PATIENTS WITH SOLID TUMORS WITH SOMATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR, HER2, HER3) MUTATIONS OR EGFR GENE AMPLIFICATION

Neratinib is an experimental drug in this study andis being studied as a potential new treatment for patients with can…

Neratinib is an experimental drug in this study andis being studied as a potential new treatment for patients with cancers whichcarry specific mutations in genes of the ERBB family of growth factor receptors(EGFR, ERBB2, ERBB3, or ERBB4 also referred to as HER1, HER2, HER3, or HER4).  Growth factor receptors are proteins present onthe cell surface that receive signals on when to divide and grow. Thesemutations are believed to have a role in abnormal growth of cells that can leadto oncogenesis, which is the transformation of a normal cell to a cancercell.  An experimental or investigationaldrug means it has not been approved by the US Food and Drug Administration (USFDA) for these indications.

 

This study will enroll patients who have any solidtumors that have mutations in EGFR mutations, ERBB2 or ERBB4 including but notlimited to bladder/urinary tract cancer, biliary tract, gastroesophageal(includes esophageal, gastro-esophageal and gastric cancers), breast, solidtumors not otherwise specified (ERBB2 and ERRB4), cervical, lung, colorectaland ovarian cancer. The reason why neratinib is being tested in patients withthese types of cancers is because it is believed that when an ERBB2, ERBB 4 orEGFR mutation occurs in a tumor, it will help the tumor grow and neratinib maydecrease the effect of these mutations on cancer growth.

 

The purpose of thisstudy is to find out what effects, good and/or bad, neratinib, either by itself(monotherapy) or in combination with other drugs has in solid tumors harboringsomatic EGFR mutations, ERBB2 or ERBB4 mutations.

Some of the eligibility criteria include:

  • Participants must be 18 or older.
  • Patient must have the ability to understand and sign an approved informed consent form (ICF).
  • Patient must have a confirmed diagnosis of cancers with mutations in ERBB family
Note: This is only apartial list of eligibility criteria. Please contact the Robert H. Lurie ComprehensiveCancer Center of Northwestern University for complete screening information ifyou are interested in this clinical trial.
Mahalingam, DevalingamMahalingam, Devalingam
  • Map it 201 East Huron Street Suite 12-160​
    Chicago, IL
NCT01953926 STU00206494
More Info

For more information on this study please contact us:

Study Coordinator 1-855-NU-STUDY
Copy
(xIRB) NCI 9767: An Open Label, Multicenter, Single arm Phase II study to evaluate the Activity and Tolerability of the novel mTOR Inhibitor, MLN0128 (TAK-228), in patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the urothelial tract whose tumors harbor a TSC1 and/or TSC2 mutation.
The purpose of this study is to test any good and bad effects of the study drug called MLN0128 (TAK-228). This study is being done to see if MLN0128 (TAK-228) is effective in treating this type of cancer.
• Participants must be 18 years or older
• Participants must have a urinary tract cancer that has spread because the cancer has a mutation in TSC1 and/or TSC2 genes.
• Participants must have already been treated with chemotherapy, but their disease is still growing
Morgans, AliciaMorgans, Alicia
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03047213 STU00206603
More Info

For more information on this study please contact us:

Study Coordinator 1-855-NU-STUDY
Copy
Phase Ib, open label, combination study of nintedanib with 5- azacitidine in acute myeloid leukemia characterized by HOX gene overexpression, that are not candidates of intensive chemotherapy
The purpose of this study is to find the appropriate dose of the study drug nintedanib when combined with aza…
The purpose of this study is to find the appropriate dose of the study drug nintedanib when combined with azacitidine and the associated side effects of the combination in older adults with AML characterized by HOX gene overexpression who are not interested in or not considered fit for standard intensive chemotherapy. The use of the study drug nintedanib in this study is investigational. “Investigational” means that this medication has not yet been approved by the FDA to treat this type of cancer. Azacitidine received FDA Approval in 2004 for myelodysplastic syndrome (a blood cancer related to AML) and has a National Comprehensive Cancer Network (NCCN) guideline recommendation for treatment of older adults who are not candidates for or decline intensive remission induction therapy. We expect participation to continue in this study based on each participant’s response to the drug, and ability to tolerate treatment. Participants may continue to receive study treatments for 6 cycles (one cycle is 28 days long). If the 6 cycles of treatment is completed, participants may be moved on to a maintenance phase of treatment. Treatment will continue until the participant’s leukemia gets worse, or they experience serious side effects, have a break in treatment for more than 56 days or the study doctor feels it is best for study treatments to stop.

You may be eligible for this research study if you have a specific type of disease of the blood cells and bone marrow called acute myeloid leukemia, and you have declined standard intensive chemotherapy or it has been medically determined not to be in your best interest. It may also be that your disease has returned after initial treatment and disappearance of evidence of cancer, or you may not have responded to treatment during initial therapy. You may be eligible to receive treatment on this trial if your leukemia cells have overexpression (abnormal amount) of HOX genes. 

Altman, Jessica KAltman, Jessica K
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03513484 STU00206525
More Info

For more information on this study please contact us:

Study Coordinator 1 312 695 1102
Copy
Next-Generation sequencing of cell-free circulating tumor DNA in locally invasive bladder cancer
bloodstream. These pieces are called cell-free circulating tumor DNA (cfDNA). Recent studies in lung and breast cancers have shown that cfDNA can be screened for certain mutations to detect and follow t…
bloodstream. These pieces are called cell-free circulating tumor DNA (cfDNA). Recent studies in lung and breast cancers have shown that cfDNA can be screened for certain mutations to detect and follow the growth of a patient’s tumor. This study aims to apply this technique to bladder cancer and to identify specific mutations unique to varying stages of bladder cancer. This technology has been applied to other cancers but has not yet been studied in bladder cancer. We plan to determine whether this technology is able to identify genetic mutations linked to bladder cancer.
Patients age 18-89 years old with early invasive (T1) and muscle invasive (T2+) bladder cancer .
Meeks, Joshua JMeeks, Joshua J
STU00206645
More Info

For more information on this study please contact us:

312 695 8146
Copy
A randomized, double-blind, multi-centre, placebo-controlled, parallel-arm phase 2 trial to assess safety, efficacy and pharmacokinetics of CD11301 0.03% and 0.06% gel in the treatment of Cutaneous T-Cell Lymphoma (CTCL), stages IA, IB and IIA (Protocol #RD.03.SPR.104003)
This study is being done to …
This study is being done to assess the efficacy and safety of two concentrations of Resuiqimod gel in the treatment of CTCL (stage IA, IB, IIA). In addition, this study will test the systemic effect of Resiquimod gel on lesions distant from the treatment areas.
Must be 18 years or older with a clinical diagnosis of Cutaneous T Cell Lymphoma with at least three distinct lesions, including one distant lesion.
Guitart, JoanGuitart, Joan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03292406 STU00206325
More Info

For more information on this study please contact us:

Jimenez, Javier 312 503 5903
Copy
A Phase 1/2a, Multicenter, Open Label Study of LYC-55716 in Adult Subjects with Locally Advanced or Metastatic Cancer

LYC-55716 is an investigational drug that is beingdeveloped by Lycera Corporation (the “Sponsor” of the research Study) for usein locally advanced or metastatic tumors. “Inve…

LYC-55716 is an investigational drug that is beingdeveloped by Lycera Corporation (the “Sponsor” of the research Study) for usein locally advanced or metastatic tumors. “Investigational” means that LYC-55716has not been approved by the United States Food and Drug Administration (FDA)for use as a prescription or over-the-counter medication to treat a certaincondition.  At Northwestern University, about8 people are expected to be enrolled in the phase 2 portion of this researchstudy out of 120 people in the entire study.

 

The primary purposeof this Study is to determine how safe the study drug is, identify the dose ofthe drug that can be taken safely (phase1 part) and what effect the study drug hason your disease (phase 2 part). If you are found to qualify and decide toenroll in this study, you will enroll in the phase 2 part and undergo studytreatment for approximately six months. You will take three LYC-55716 tabletsorally, twice daily, approximately 12 hours apart for about 24 weeks. If youshow signs of clinical benefit, and tolerate LYC-55716 adequately, you mayreceive additional cycles of treatment beyond 24 weeks until your disease getsworse or you experience intolerable side effects. You will also be followed forabout 1 year after your last dose of the study drug to see how you are doing.

Some of the eligibility criteria include:

  • Participants must be 18 or older.
  • Patient must have the ability to understand and sign an approved informed consent form (ICF).
  • Patient must locally advanced or metastatic cancer.
Note: This is only apartial list of eligibility criteria. Please contact the Robert H. Lurie ComprehensiveCancer Center of Northwestern University for complete screening information ifyou are interested in this clinical trial.
Mahalingam, DevalingamMahalingam, Devalingam
  • Map it 201 East Huron Street Suite 12-160​
    Chicago, IL
NCT02929862 STU00206768
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
(xIRB NCI) ECOG-ACRIN 4151: A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
The purp…
The purpose of this research study is to determine whether an autotransplant improves survival in MCL patients who have achieved an excellent (MRD-negative) first complete remission (CR). An autotransplant is a procedure in which a high dose of chemotherapy is given, in hopes of reducing the amount of lymphoma more than what standard chemotherapy would generally accomplish. In order to allow the body to safely recover from the high-dose chemotherapy, blood stem cells are collected (prior to the high-dose chemotherapy) and then re-infused after the high dose chemotherapy is cleared from the body.
• Participants must be 18 years or older
• Participants must be diagnosed with mantle cell lymphoma, a type of blood cancer.
Winter, Jane NormaWinter, Jane Norma
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03267433 STU00207302
More Info

For more information on this study please contact us:

Study Coordinator 1-855-NU-STUDY
Copy
Partial Wave Spectroscopy for Urine Cytology Analysis
Bladder cancer is the fourth most common in men and sixth overall and while approximately 75% of patients will be diagnosed with superficial cancer, there is a high rate of recurrence. Currently, diagnosis and surveillance require invasive testing…
Bladder cancer is the fourth most common in men and sixth overall and while approximately 75% of patients will be diagnosed with superficial cancer, there is a high rate of recurrence. Currently, diagnosis and surveillance require invasive testing – cystoscopy (using a scope to look inside the bladder). While urine tests are used as part of the workup and follow-up, the current urine tests are limited. Our goal is to test a new technique that looks at individual cells to see if we can improve cancer detection. Cells that line the bladder are frequently shed into the urine, and therefore, these can be studied simply by providing a urine sample and without an invasive test. Our hope is that this urine test will be able to improve initial diagnosis and follow-up for patients with bladder cancer This is an investigational technique and is not approved by the USFDA.
Patients age 18-89 with a confirmed pathologic diagnosis of urothelial carcinoma of the bladder.
Meeks, Joshua JMeeks, Joshua J
STU00206508
More Info

For more information on this study please contact us:

Meeks, Joshua J 312 695 8146
Copy
Palbociclib after CDK and Endocrine Therapy (PACE): A Randomized Phase II study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer

This research study is studying three combinations of drugs as treatments for this type of cancer:

  • Ar…

This research study is studying three combinations of drugs as treatments for this type of cancer:

  • Arm A: fulvestrant 
  • Arm B: fulvestrant with palbociclib 
  • Arm C: fulvestrant with palbociclib and avelumab 

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. “Investigational” means that the intervention is being studied and the researchers are trying to find out more about it— for example, the side effects it may cause, and the activity of a drug, or combination of drugs, against a cancer. 

In this research study, we are evaluating the activity of fulvestrant alone, fulvestrant and palbociclib, or fulvestrant, palbociclib, and avelumab in participants with metastatic hormone receptor positive breast cancer that has previously stopped responding to prior palbociclib therapy, or another medication in the class of therapy called CDK 4/6 inhibitors.

You may be eligible for this research study if you have breast cancer that has spread to other parts of your body (metastatic cancer) and your cancer is hormone receptor positive. This study is designed for patients who have previously had exposure to the medication palbociclib, or another medication in the class of therapy called CDK 4/6 inhibitors.

Cristofanilli, MassimoCristofanilli, Massimo
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03147287 STU00207256
More Info

For more information on this study please contact us:

Study Coordinator 1 312 695 1102
Copy
DRUG GRN-1201-002: A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects with Non-Small Cell Lung Cancer with High PD-L1 Expression

This is the first study of GRN-1201/sargramostim in combination with pembrolizumab in humans. The researchers want to fin…

This is the first study of GRN-1201/sargramostim in combination with pembrolizumab in humans. The researchers want to find out what effects, good or bad, this combination has on people with newly diagnosed metastatic non-small cell lung cancer (NSCLC) expressing PD-L1 and whose tumor biopsy samples express PD-L1. 

The study drug, GRN-1201, is a type of cancer vaccine made up of four peptides (short chains of amino acids) that can cause an immune system response against cancer cells. The study drug is being tested when it is added to another drug called pembrolizumab, an approved medicine to treat NSCLC which has spread (metastatic), because it may cause a response by the immune system against the tumor. GRN-1201 is considered an "investigational" drug. An investigational drug is one that is not approved by the Food and Drug Administration (FDA) for use or sale in the United States. Each dose of GRN-1201 will be 3.0 mg of each peptide given together with a low dose (75 mcg) of another drug called rhGM-CSF (sargramostim, also called Leukine®). Sargramostim is an FDA approved drug which may enhance (increase) your body's immune response to GRN-1201. GRN-1201/sargramostim in combination with pembrolizumab has not been tested before and is not FDA approved. 

You may be eligible for this research study if you have newly diagnosed metastatic non-small cell lung cancer (NSCLC) with high levels of PD-L1. 
Villaflor, VictoriaVillaflor, Victoria
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03417882 STU00206591
More Info

For more information on this study please contact us:

Study Coordinator 1 312 695 1102
Copy
(xIRB) NCI CIRB: SWOG 1612: A RANDOMIZED PHASE II/III TRIAL OF “NOVEL THERAPEUTICS” VERSUS AZACITIDINE IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS), AGE 60 OR OLDER (LEAP: LESS-INTENSE AML PLATFORM TRIAL)
This study includes a screening…
This study includes a screening step and a treatment step. The purpose of the screening step is to allow researchers to learn if a certain blood and bone marrow test (called a biomarker) can help predict how a person’s AML/MDS will respond to study drugs. The purpose of the treatment step of this study is to compare any good and bad effects of using different new treatment options to one of the current standard treatment options. The investigators will keep testing new treatments to see if they have any different effects on patients and their cancer when compared to the standard.
You may be able to take part in this study if you have acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) and you and/or your doctor did not think you should get intensive chemotherapy.
Frankfurt, OlgaFrankfurt, Olga
  • Map it 201 E. Huron St.
    Chicago, IL
STU00207638
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
DRUG VT1021-01: A Phase 1 Study Evaluating the Safety, Pharmacology, and Preliminary Activity of VT1021 in Patients with Advanced Solid Tumors
The purpose of this research study to find a dose of an investigational drug called VT1021 thatwould be safe in humans and to preliminarily test whether or no…
The purpose of this research study to find a dose of an investigational drug called VT1021 thatwould be safe in humans and to preliminarily test whether or not VT1021 is useful against cancer.The research study is also being done to learn about the pharmacokinetics of VT1021.Pharmacokinetics means how the body takes the drug into the blood, how the drug spreads outor is distributed in the body, and how it is broken down and removed from the body. VT1021 is an experimental, or investigational, drug that may slow down (inhibit) cancer spreadingthroughout the body (metastasis).
Participants who have been diagnosed with an advanced solid tumor cancer for which standard chemotherapy is no longer effective.
Mahalingam, DevalingamMahalingam, Devalingam
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03364400 STU00207309
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585).
The purpose of this s…
The purpose of this study is to test the safety, efficacy, and tolerability of the research study drug, pembrolizumab (MK-3475) in combination with cisplatin and capecitabine or 5- fluorouracil (5-FU).

You may be eligible for this research study if you have gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Benson III, Al BBenson III, Al B
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03221426 STU00207611
More Info

For more information on this study please contact us:

Study Coordinator 1 312 695 1102
Copy
Protocol ATI001-102 Expansion Substudy: Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects with Recurrent or Progressive Glioblastoma
This research study involves two investigational drugs, veledimex, an activator ligand (INXN-1001) in combination with an Adenovirus Vector Engineered to Express hIL-…
This research study involves two investigational drugs, veledimex, an activator ligand (INXN-1001) in combination with an Adenovirus Vector Engineered to Express hIL-12 (INXN-2001). IL-12 is a protein that may improve the body's natural response to disease by enhancing the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor. The main purpose of this study is to evaluate the safety and tolerability of a single tumor injection of INXN-2001 given in combination with oral veledimex.
Inclusion Criteria: 1. Male or female subjects ≥ 18 and ≤ 75 years of age. 2. Histologically confirmed supratentorial glioblastoma from archival tissue. 3. Evidence of tumor recurrence/progression by MRI (RANO criteria) post standard initial therapy. 4. Previous standard of care anti-tumor treatment including surgery and/or biopsy and chemoradiation. 5. Able to undergo standard MRI scans with contrast agent. 6. Karnofsky Performance Status ≥ 70. 7. Adequate bone marrow reserves and liver and kidney function. 8.Male and female subjects must agree to use a highly reliable method of birth control. Exclusion Criteria: 1. Radiotherapy within 4 weeks or less prior to starting first veledimex dose. 2. Subjects with clinically significant increased intracranial pressure or uncontrolled seizures. 3. Known immunosuppressive disease, autoimmune conditions, and /or chronic viral infections. 4. Use of systemic antibacterials, antifungals or antivirals for the treatment of acute clinically significant infection. 5. Use of enzyme-inducing anti-epileptic drugs (EIAED) within 7 days prior to the first dose of study drug. 6. Other concurrent clinically active malignant disease requiring treatment. 7. Nursing or pregnant females. 8. Prior exposure to veledimex. 9. Presence of any contra-indication for a neurosurgical procedure.
Lesniak, MaciejLesniak, Maciej
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02026271 STU00207771
More Info

For more information on this study please contact us:

Amidei, Christina 312 695 9124
Copy
NU 18U07: Clinical, Environmental, Genetic and Genomic Profile of Men with Early-Onset Aggressive Prostate Cancer

This study is being done because physicians do not completely understand the progressive biology of prostate cancer. Hence, the study aims to gather a better understanding of the clini…

This study is being done because physicians do not completely understand the progressive biology of prostate cancer. Hence, the study aims to gather a better understanding of the clinical and molecular features of prostate cancer patients who are younger than or equal to 60 years of age.

In this research project the researchers aim to characterize the different clinical, environmental, genetic and genomic profiles of men who present with early-onset (less than 60 years old) metastatic prostate cancer that spread to either lymphnodes or other parts of the body at diagnosis or who develop metastases shortly after local therapy. Specifically the investigators will collect information on race, ethnicity, family history, environmental, hormonal levels, metastatic disease extent and distribution. They will also evaluate the tumor tissue for genetic changes and correlate that with other clinical factors. The investigators will also determine if there are inherited genetic changes. Similarly for patients with spread prostate cancer who were treated with hormone therapy + docetaxel or abiraterone/prednisone with cancer progression (less than 1 year from start of therapy) and developed disease progression the investigators will assess clinical and genomic predictors of prostate cancer progression and resistance to therapy.

You may be eligible for this study if you are a male who has been diagnosedwith either advanced or metastatic prostate cancer. Advanced means that the cancer has spreadoutside the prostate gland including pelvic lymph nodes and metastatic means that the cancerhas spread to other parts of your body. 

One group of participants will be less than 60 years ofage with advanced or metastatic prostate cancer at diagnosis and the other group will be menwho have metastatic prostate cancer who were treated with hormone therapy with docetaxel orabiraterone/prednisone and the cancer is progressing.

Hussain, MahaHussain, Maha
  • Map it 201 E. Huron St.
    Chicago, IL
STU00207711
More Info

For more information on this study please contact us:

Study Coordinator 1 312 695 1102
Copy
(xIRB NCI CIRB) ALLIANCE A041501: A PHASE III TRIAL TO EVALUATE THE EFFICACY OF THE ADDITION OF INOTUZUMAB OZOGAMICIN (A CONJUGATED ANTI-CD22 MONOCLONAL ANTIBODY) TO FRONTLINE THERAPY IN YOUNG ADULTS (AGES 18-39 YEARS) WITH NEWLY DIAGNOSED PRECURSOR B-CELL ALL
The first purpose of this study is to te…
The first purpose of this study is to test the safety of adding a new drug called inotuzumab to the usual chemotherapy drugs. The second purpose of this study is to compare any good and bad effects of using inotuzumab along with the usual chemotherapy treatment to using the usual treatment alone. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. Inotuzumab is investigational and is not FDA-approved.
You may be able to take part in this study if you have acute lymphoblastic leukemia (ALL) and are 18 to 39 years old.
Dinner, ShiraDinner, Shira
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03150693 STU00208162
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
NU 18U08: Blood Based Prognostic Biomarkers of Metastatic Prostate Cancer

This is an observational study in which no treatment decisions will be made based on the findings of this study. This study is being done because physicians do not completely understand the progressive biology of prostate ca…

This is an observational study in which no treatment decisions will be made based on the findings of this study. This study is being done because physicians do not completely understand the progressive biology of prostate cancer. Hence, the study aims to gather a better understanding of some specific biomarkers (molecular markers) and their relation to the clinical picture of prostate cancer patients. The researchers aim to collect blood samples which will be used to evaluate biomarkers in Circulating Tumor cells (CTCs) and correlate their expression to disease prognosis (the likely course your disease will take) and response to therapy. They will collect information including age, race, ethnicity, family history of prostate cancer and other cancers, prostate cancer grade, tumor treatment, response to treatment, duration of survival and metastatic disease extent and distribution. 

A patient may be eligible for this research study if he has metastatic prostate cancer for which he will start hormone therapy (androgen deprivation therapy [ADT] plus abiraterone [Zytiga] if the cancer is castration sensitive, or with abiraterone or enzalutamide [Xtandi] if the cancer is castration resistant).

Hussain, MahaHussain, Maha
  • Map it 201 E. Huron St.
    Chicago, IL
STU00207694
More Info

For more information on this study please contact us:

Study Coordinator 1 312 695 1102
Copy
A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy.

This is a study to learn more about mucosal and a…

This is a study to learn more about mucosal and acral lentiginous melanoma therapy. We are collecting blood and tissue samples from people who will receive nivolumab in combination with ipilimumab treatment for their mucosal and acral lentiginous melanoma. The nivolumab and ipilimumab combination is approved by the U.S. Food and Drug Administration for the treatment of patients with advanced melanoma and therefore is considered a standard treatment of this disease.

However, the disease we call melanoma can present in different fashions, which may influence its behavior and response to therapy. Melanomas that start on mucous membranes are called mucosal and those that develop on the palms and soles of the feet are designated “acral lentiginous.” These rare subtypes of melanoma may behave differently from the more common melanomas that begin on sun exposed skin surfaces. Research on blood, tissues, and medical information is one way to learn more about diseases. We can learn how different people respond to different cancer treatments.

The purpose of this study is to determine which participants with melanoma respond best to nivolumab and ipilimumab treatment and to identify tumor and blood based markers that may predict response to the combination. To do this, participants will be asked to submit tumor tissue samples from initial tumor specimen and blood samples before and during treatment with nivolumab and ipilimumab for their advanced melanoma. By collecting participant information on response to therapy and correlating it with analyses of blood and tumor samples we hope to determine which patients are most appropriate for this treatment and potentially factors that might suggest patients should be considered for a different treatment.

You may be eligible for this research study if you have been diagnosed with mucosal and/or acral lentiginous melanoma.

Chandra, SunandanaChandra, Sunandana
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02978443 STU00207669
More Info

For more information on this study please contact us:

Study Coordinator 1 312 695 1102
Copy
DRUG D6070C00004: A Multiarm, Open-label, Multicenter, Phase 1b/2 Study to Evaluate Novel Combination Therapies in Subjects with Previously Treated Advanced EGFRm NSCLC

This study is being conducted to test 2 experimental drugs, oleclumab (MEDI9447) and osimertinib, given in combination (tog…

This study is being conducted to test 2 experimental drugs, oleclumab (MEDI9447) and osimertinib, given in combination (together), to treat advanced epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). 

Oleclumab is a laboratory-made antibody that binds to a molecule called CD73. Naturally occurring, antibodies are proteins, made by the immune system, that fight infections and other diseases. The immune system can recognize cancer cells, and in some circumstances control or even eliminate tumors. In the body, CD73 produces a molecule called adenosine. Too much adenosine can suppress the activity of the immune system. Oleclumab binds to CD73, reducing CD73’s ability to produce adenosine. This reduction in adenosine may boost the activity of the immune system, and prevent cancer growth. Additionally, it has been shown that patients with EGFRm NSCLC have higher levels of the CD73 protein in their tumors compared to patients with lung cancer that lacks the mutation in the EGFR gene. Osimertinib blocks the actions of a protein in the body called tyrosine kinase. It has been approved by the United States Food and Drug Administration (FDA) for the treatment of a type of EGFRm NSCLC that is linked to a specific change in the EGFR gene called the T790M mutation. The use of osimertinib is “experimental” in this study because the use of osimertinib combined with oleclumab as a cancer treatment has not been approved by any authority that regulates new medicines. This means that treatment with osimertinib is not standard care for treating this type of cancer. 

The study will look at whether this combination of oleclumab and osimertinib, because of the way they work, may improve the outcome in subjects with your type of cancer. The purposes of this study are to find the doses of oleclumab and osimertinib, given in combination, which are safe and well tolerated, to determine what side effects may occur and to confirm how well the treatment works for EGFRm NSCLC. The study will also measure the amount of oleclumab and osimertinib in your blood at various times, whether or not your body makes antibodies against oleclumab, and the effect oleclumab combined with osimertinib has on your cancer. Antibodies against oleclumab could reduce the active level of the study drugs in your blood and reduce the effects of the study drugs on your cancer.

You may be eligible for this research study if you have advanced epidermalgrowth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) and your cancer is advanced and is worsening despite previous treatments that have included a medicine whichworks to block the EGFR gene.
Chae, Young KwangChae, Young Kwang
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03486314 STU00207982
More Info

For more information on this study please contact us:

Study Coordinator 1 312 695 1102
Copy
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716)

The purpose of this study is to:

- See how well the study drug, pembrolizumab, works compared to placebo in keeping your cancer from coming back …

The purpose of this study is to:

- See how well the study drug, pembrolizumab, works compared to placebo in keeping your cancer from coming back or spreading. A placebo looks like the study drug but has no medicine in it.

- Test the safety of the study drug

- See how your body handles the study drug.

- Male/female patients at least 18 years of age who have surgically resected and histologically/pathologically confirmed new diagnosis of Stage IIB or IIC cutaneous melanoma

- Patients must not have been previously treated for melanoma beyond complete surgical resection of the current primary melanoma lesion

- Patients must be able to start study treatment no more than 12 weeks after full surgical resection.

Chandra, SunandanaChandra, Sunandana
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03553836 STU00208266
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
NU 18I01: A Phase 2 study of pembrolizumab in combination with pelareorep in patients with advanced pancreatic adenocarcinoma
This study involves the use of an investigational drug called pelareorep (Reolysin®).“Investigational” means that the drug pelareorep has not been approved by the U.S. Fo…
This study involves the use of an investigational drug called pelareorep (Reolysin®).“Investigational” means that the drug pelareorep has not been approved by the U.S. Food &Drug Administration (FDA) for treating pancreatic adenocarcinoma.The primary goal is to see if a treatment using both pelareorepand pembrolizumab has any effect on pancreatic cancer and also to evaluate the safety ofthis combination of these two drugs. Pelareorep is an investigational product that uses a type ofvirus called reovirus. This virus is commonly found in natural environments throughout the world(such as ponds) and is associated with minor breathing difficulties and stomach upsets inhumans. Infection of cancer cells by this virus is expected to be able to slow cancer lesiongrowth and kill cancer cells.  Pembrolizumab is a drug thatworks on stimulating the immune system to fight the cancer cells and it is currently approvedfor the treatment of other tumors (melanoma and lung). It is not presently known if it will help inthe treatment of pancreatic cancer. The combination of pembrolizumab and pelareorep isexpected to be able to determine if pelareorep will or will not stimulate the immune systemand make it more responsive to therapy with pembrolizumab.
Participants with advancedpancreatic adenocarcinoma.
Mahalingam, DevalingamMahalingam, Devalingam
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03723915 STU00207577
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
A Phase 2, Randomized, Biomarker-driven, Clinical Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with an Exploratory Arm in Patients with Newly Diagnosed High-Risk AML and Exploratory Arms with Varying Levels of MCL-1 Dependence

The purpose of this research study is to …

The purpose of this research study is to determine the effectiveness (how well something works) and safety of an “investigational” compound called alvocidib when used in a combination chemotherapy regimen in patients with acute myeloid leukemia (AML) who have varying levels of MCL-1 (human gene) dependency. “Investigational” means that the Food and Drug Administration (FDA) has not yet approved this drug as a prescription medicine; it is only available through research studies like this. 

Alvocidib was previously known as flavopiridol. Alvocidib is an investigational product being developed by Tolero Pharmaceuticals in AML. Alvocidib will be one of three drugs used in the combination chemotherapy treatment regimen. The other drugs are cytarabine and mitoxantrone. Both cytarabine (also known as Ara-C) and mitoxantrone are standard of care for the treatment of patients with AML. However, the three-drug combination of alvocidib with cytarabine and mitoxantrone (abbreviated “ACM”) is an experimental combination. (ACM has also been referred to as FLAM).

You may be eligible for this research study if you have acute myeloid leukemia (AML) that has come back after initial treatment (relapsed) or because you did not get a complete response from your initial treatment (refractory) or you have been newly diagnosed with highrisk (NDHR) AML. As part of the initial pre-screening process, you had a bone marrow aspirate performed and tested that showed you have AML that expresses a protein that may predict whether you will respond to treatment with ACM (an experimental combination).

Frankfurt, OlgaFrankfurt, Olga
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02520011 STU00208084
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
A Randomized Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma

In the study, the treatment period is divided into cycles that are 4 weeks long.Relatlimab/nivolumab FDC or nivolumab alone…

In the study, the treatment period is divided into cycles that are 4 weeks long.Relatlimab/nivolumab FDC or nivolumab alone will be given once every 4 weeks (every 28 days) of each treatment cycle.Participants will continue to receive treatment depending on how they tolerate the study drug(s) and how their cancer responds. After completing all study treatments or after the treatment has been stopped for other reasons, participants will be asked to continue with follow-up visits to monitor for potential benefits or side effects they may be experiencing from study treatment.  Participants may be followfor up to 5-7 years total.   

Chandra, SunandanaChandra, Sunandana
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03470922 STU00207656
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
DRUG GC P#05.01.020: A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, Umbilical Cord Blood-derived, Stem and Progenitor Cells, versus Unmanipulated Umbilical Cord Blood for Patients with Hematological Malignancies
The main purpose of this study…
The main purpose of this study is to determine whether NiCord® transplants are better than transplants with standard, unmanipulated cord blood units.
You may be eligible for this study if you have a blood cancer that is being treated with allogeneic stem cell transplantation. 
Frankfurt, OlgaFrankfurt, Olga
  • Map it 201 E. Huron St.
    Chicago, IL
STU00208388
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
(xIRB NCI CIRB) Alliance A011401: Randomized Phase III Trial Evaluating The Role Of Weight Loss In Adjuvant Treatment Of Overweight And Obese Women With Early Breast Cancer
This study is being done to see if losing weight may help prevent breast cancer from coming back. Previous studies have fou…
This study is being done to see if losing weight may help prevent breast cancer from coming back. Previous studies have found that women who are overweight or obese when their breast cancer is found have a greater risk of their breast cancer recurring, as compared to women who were thinner when their cancer was diagnosed. At this time we do not know whether or not losing weight will reduce the risk of breast cancer returning. This study seeks to determine whether or not the higher risk for breast cancer recurrence in women who are overweight or obese when they are diagnosed with breast cancer could be reduced or eliminated if weight is lost. It is important to note that we do not know how much weight would need to be lost to lower the risk of breast cancer recurrence, or whether this strategy would work for all women. This study willhelp to show researchers whether weight loss programs should be a part of breast cancer treatment.

This study seeks to determine whether or not the higher risk for breast cancer recurrence in women who are overweight or obese when they are diagnosed with breast cancer could be reduced or eliminated if weight is lost.

 

Donnelly, EricDonnelly, Eric
  • Map it 201 E. Huron St.
    Chicago, IL
STU00208895
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
ECOG-ACRIN 6174: A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma (NCT)

We are asking you to take part in a research study. We do research studies to try to answer questions about how to prevent, di…

We are asking you to take part in a research study. We do research studies to try to answer questions about how to prevent, diagnose, andtreat diseases like cancer.This study is being done to answer the following question: Can we lower the chance of your cancer growing back by adding a study drug after your surgery?

We are doing this study because we want to find out if this approach is better or worse than the usual approach for your Merkel Cell Carcinoma. The usual approach is defined as care most people get after surgery to remove the cancer.

We are asking you to take part in this research study because you have stage I-IIIB Merkel Cell Carcinoma (MCC) that has been removed by surgery.

Chandra, SunandanaChandra, Sunandana
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03712605 STU00208944
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
Utilization of Clinomic Outcomes, Patient-Derived Xenografts (Avatars), and Next Generation Sequencing Data for the Identification of Alternative Actionable Targets and Therapeutic Response Prediction in Cholangiocarcinoma

The purpose of this study is to gather information about your cancer and th…

The purpose of this study is to gather information about your cancer and the genetic makeup of your tumor tissue. In this study, we are looking for specific biomarkers using genetic testing and animal models. We are interested in learning about the relationship between your cancer and the different types of genetic markers in your tumor tissue to identify possible new treatment methods in the future. 

A portion of your tumor will be sent for routine genomic analysis. The tests known as next generation sequencing or “NGS” are being done on your cancer tissue samples as part of your routine clinical care. These routine tests will be performed whether you participate in this study or not. Another small portion of that tumor will be placed in a mouse to grow (xenograph or “avatar”) from which more genetic analyses will be performed. 

You may be eligible for this research study if you have a diagnosis of a type of cancer called cholangiocarcinoma, and you are planning to have either a surgical resection or a biopsy of your tumor at Northwestern University, in which you agree to have a portion of your tumor sent for routine genomic analysis to potentially help you and your physician make treatment decisions now or in the future. 

Benson III, Al BBenson III, Al B
  • Map it 201 E. Huron St.
    Chicago, IL
STU00208589
More Info

For more information on this study please contact us:

Study Coordinator 1 312 695 1102
Copy
NU 18I03: Pilot study of nivolumab in combination with Therasphere (yttrium-90) for treatment of hepatocellular carcinoma (HCC) with intent for resection
The purpose of this study is to evaluate the feasibility of using nivolumab in combination with Y90(Therasphere) to decrease the occurrence of your…
The purpose of this study is to evaluate the feasibility of using nivolumab in combination with Y90(Therasphere) to decrease the occurrence of your HCC from coming back. Also another purposeis to evaluate the efficacy (the effect on the tumor) of nivolumab, when given with standard ofcare Y-90 (Therasphere) in patients. Another purpose of the study is to see what tumor characteristics are different among patientswho undergo resection versus those who do not undergo resection. 
Participants who have advancedhepatocellular carcinoma (HCC). 
Kulik, Laura MKulik, Laura M
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03812562 STU00208542
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
A Phase 1/2, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome
This study involves research about the…
This study involves research about the study drug MGD006. MGD006 is similar to an antibody - a substance in the blood that helps remove foreign substances. MGD006 is made to attach to your cancer cells and to T-cells - a part of your immune system - that may help your immune system kill the malignant cells. MGD006 is an investigational drug which means it has not been approved by the Unites States Food and Drug Administration (FDA) for the treatment of AML or any other cancers. MGD006 has been tested in animals, but this is the first time it will be given to humans to be tested as a possible treatment for AML. The purpose of this study is to find the answers to these research questions:

  • What are the side effects of MGD006?
  • What is the highest dose of MGD006 that can be given safely?
  • How long does MGD006 stay in the blood?
  • How long does it take for MGD006 to leave the body?
  • Is MGD006 a possible treatment for AML?

  • Patients must have a confirmed diagnosis of primary or secondary AML or MDS with a risk category of Intermediate-2 or High Risk
  • Patients must be unlikely to benefit from recommended standard of care defined by any one of the following criteria:
    • leukemia refractory to at least 2 induction attempts,
    • leukemia in 1st relapse with initial CR duration < 6 months
    • leukemia in 1st relapse following at least 1 unsuccessful salvage attempt
    • leukemia in 2nd or higher relapse
    • prior treatment failure with at least four cycles of a hypomethylating agent
  • Patients with MDS must have experienced treatment failure with induction therapy or at least one cycle of hypomethylating therapy and have at least 10% bone marrow blasts.
Altman, Jessica KAltman, Jessica K
  • Map it 201 E. Huron St.
    Chicago, IL
STU00208838
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
An Open Label, Pilot Study Evaluating the Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced Alopecia

This study will test if low-dose oral minoxidil has aneffect on permanent chemotherapy-induced alopecia (defined as hair loss afterthe completion of a chemotherapy re…

This study will test if low-dose oral minoxidil has aneffect on permanent chemotherapy-induced alopecia (defined as hair loss afterthe completion of a chemotherapy regimen that persists for over six months). Inthis study, you will receive the study drug; there is no placebo option. Theeffectiveness and safety of the treatment will be determined by a range of assessments,including biopsies, images, and subjective evaluation of perceived hair growth.

Age 18 and above with a diagnosis of permanentchemotherapy-induced alopecia and agree to use contraception for the durationof the study.

Choi, JenniferChoi, Jennifer
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03831334 STU00206882
More Info

For more information on this study please contact us:

Kosche, Cory 312 503 5944
Copy
A Phase II Randomized Study of Adjuvant Versus Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High Risk Melanoma

This study is being done to answer the following question: How does treating melanoma with the study drug pembrolizumab, before versus after surgery affect t…

This study is being done to answer the following question: How does treating melanoma with the study drug pembrolizumab, before versus after surgery affect the disease?

We are doing this study because we want to find out which approach is better for treating high-risk melanoma. If you decide to take part in this study, you will eitherget treatment with pembrolizumab after your surgery, or you will be treated withpembrolizumab for a few weeks before surgery, then undergo surgery, and getmore pembrolizumab after your surgery.After you finish your study treatment, your doctor willcontinue to follow your condition for up to 10 years after you register to thestudy.  Your doctor will watch you forside effects and to see how your cancer affects you.  You will have clinic visits periodically fromthe time you stop taking treatment until 10 years after you register to the study.

 

We are asking you to take part in this research study because you have melanoma which is ready for removal by surgery.

Chandra, SunandanaChandra, Sunandana
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03698019 STU00209408
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
DRUG 16-214-02 A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY OF THE COMBINATION OF NKTR-214 AND NIVOLUMAB OR THE COMBINATION OF NKTR-214, NIVOLUMAB, AND OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES
This is an investigational study of a drug …
This is an investigational study of a drug named NKTR-214 that will be given in combination with Opdivo® (nivolumab) or in combination with Opdivo® and other anti-cancer therapies. NKTR-214, also referred to as “study drug,” is a modified (changed in the laboratory) form of a protein called interleukin-2 (or IL-2) that is normally made by your immune system. This protein is designed to trigger other cells in your immune system to start attacking your cancer cells. IL-2 has been used for certain cancers for many years so doctors understand many of the risks and benefits.

We are asking you to take part in this research study because you have a diagnosis of: Melanoma (skin cancer). Here at Northwestern University we will only be enrolling participants who have been diagnosed with Melanoma.

Sosman, JeffreySosman, Jeffrey
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02983045 STU00208952
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
DRUG 2125-MEL-301 A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma
The purpose of the study is to compare the effectiveness of IMO-2125 given in combination with ipilimumab compared to ipilimumab given alone. …
The purpose of the study is to compare the effectiveness of IMO-2125 given in combination with ipilimumab compared to ipilimumab given alone. This is an investigational study, which means the study drug is experimental and is not approved by the U.S. Food and Drug Administration (FDA). Ipilimumab(Yervoy®) is a drug currently approved by the US Food and Drug Administration, Health Canada, the European Medicines Agency, and the Australian Therapeutic Goods Administration for the treatment of advanced melanoma. You will be randomly assigned by chance (like the flip of a coin) to receive either IMO-2125 + ipilimumab or ipilimumab alone. You have an equal chance of being put into any one of the groups. This means that you have a 1 in 2 chance of being on IMO-2125 + ipilimumab and a 1 in 2 chance of being on ipilimumabalone. The study treatment groups are: Group A: Ipilimumab and Group B:IMO-2125 + ipilimumab.  If you are assigned to GroupA, you will be given ipilimumab as an intravenous infusion (i.v., into a vein)over 90 minutes on weeks 1, 4, 7, and 10. You will receive study treatment for 10 weeks If you are assigned to GroupB, you will be given IMO-2125 as an intratumoral injection, which means it will be injected directly into a single tumor on weeks 1, 2, 3, 5, 8, 11, 16, 20 and 24. You will also be given ipilimumab as an i.v. over 90 minutes on weeks 2, 5,8 and 11. On days that you receive a combination of ipilimumab and IMO-2125,IMO-2125 will be given first. You will receive this study treatment for 24 weeks. 

We are asking you to take part in this research study because you have refractory melanoma. 

Chandra, SunandanaChandra, Sunandana
  • Map it 201 E. Huron St.
    Chicago, IL
NCT03445533 STU00209182
More Info

For more information on this study please contact us:

Study Coordinator 312 695 1102
Copy
Back to top